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Primary brain tumor affects some 18,000 adults in the United States each year 
(Silverberg et al., 1990; Merchant et al., 1997) and over 30% are high-grade anaplastic 
astrocytoma or glioblastoma multiforme (GBM) (parney et al., 1997). According to 
Kruse et al., 1989, the treatment of patients with recurrent or persistent high-grade 
gliomas represents a major therapeutic challenge. The use of conventional therapy 
consisting of surgery, followed by radiation therapy and chemotherapy for gliomas, has 
been relatively ineffective (Jaecle et al., 1994) despite the fact that these therapies are 
cytoreductive in nature (Black, 1991). Most malignancies will recur locally but may also 
XlV 
reappear at a different site within the brain. A brain tumor, once established, usually 
continues to outstrip the inhibitory action of any immuno biological defense mechanisms 
against it. Thus, malignant intracranial (IC) brain tumors represent a lethal neoplastic 
disease in which treatment has failed to extend the lifespan of affiicted individuals, with a 
GBM having a median survival rate of less than one year (Harsh et af., 1987).This has 
prompted a search for other potentially useful methods to better understand the biology of 
brain tumors as well as better ways to treat them The studies outlined herein, addressed 
the mechanisms behind the protection against tumor development provided by the 
various cells of the innate and cellular immune response in a rat brain tumor model. 
Investigations consisted of: 1) primary (1°) vaccination involving a phenotypic 
examination and functional analysis of the cells of the innate immune response and the 
cells of the adaptive immune response infiltrating an RT-2 glioma and the expression of 
the CD25 receptor; 2) 1 ° and secondary (2°) vaccination that involved a follow-up on 
survival as well as the phenotyping of cells of the leukocytic immune response; 3) 
rechallenge of long-lived rats, from Experiment 2, in the contralateral (left) hemisphere; 
and 4) acquisition of memory T lymphocytes from vaccinated rats and the use of 
lymphocyte depletion studies to determine which cells were necessary to provide a 
protective vaccination against development of tumor. Thus, this study illustrated a 
potential therapeutic strategy to develop treatments for GBM patients as well as 
providing protection against development of tumor by the use of vaccines. 
Gene ral Introduction 
ME CHANISMS UNDERLYING PROTECTION AGAINST 
RT-2 GLIOMA GENE SIS IN RAT BRAIN UTILIZING 
PRIMARY AND SECONDARY VACCINATION 
Glioma: The C lassical Pe riod 
According to Burns (1800); gliomas with their macroscopical resemblance to 
normal brain tissue were known long before Virchow (Scherer, 1940). The English 
referred to gliomas as "medullary sarcoma", as "encephaloide" by the French, and as 
"fungus medullare" by German authors (Scherer, 1940). This period was considered one 
of macroscopical research. Virchow (1863/1865) created the name "glioma" and opened 
the period of combined macroscopic and microscopic study of these n eoplasms (Scherer, 
1940). Not only did he distinguish two main groups of brain tumors, glioma and sarcoma, 
he characterized gliomas as follows: 1) "gliomas are often enormous tumors of brain-like 
appearance with slow clinical evolution"; 2) " never showing a clear limitation towards 
the normal brain tissue, but resembling more a hypertrophy of the involved parts than real 
neoplasms"; 3) "microscopically they are formed by a proliferation of glia cells and 
sometimes of glia fibers - in the latter, the tumor is hard and in the former soft" (Scherer, 
1940). These tumors correspond to what is now called "glioblastoma". Scherer, 1940 
showed that clinical and pathological differences between the two main groups of brain 
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2 
tumors - which dominate all modem glioma classification - had been perfectly 
characterized in 1865. For the next fifty years, Virchow's work determined the methods 
of glioma research. It was Strobe's (1895) work that provided the first really detailed 
microscopical description of gliomas. According to Scherer (1940), Virchow had 
described the essential differences of macroscopic behavior and mode of growth between 
"glioma" and "sarcoma". He points out that not only was Strobe able to confirm these 
differences, he was also the first to use new "specific" methods for the staining of the 
histological structures. According to Scherer, (1940), Strobe's description in all essential 
points were confirmed by Hennberg in 1897 and Storch in 1899. 
High-grade oligodendrogliollUi, anaplastic astrocytoma and glioblastoma 
multiforme (GBM) affect approximately 18,000 Americans each year with 30% of these 
tumors being GBM, the most common primary central nervous system (CNS) tumor 
(parney et a!., 1997). GBM is a rapidly progressive high-grade tumor of the supportive 
tissues of the brain. The use of conventional therapy consisting primarily of surgery, 
followed by radiation therapy, and chemotherapy for gliomas has been relatively 
ineffective (Kruse, 1994 and Merchant, 1997). A therapeutic strategy that would induce 
an immune response that targets tumor cells specifically may ultimately be a means of 
achieving their complete elimination. One of the most striking features of malignant 
glioma is the state of cellular immunosuppression observed in most patients studied over 
a period of twenty years (Roszman et al.,1991).Weliar and Fontana (1995) attributed the 
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immunodeficient state of glioma patients to several different factors: 1) immune paralysis 
resulting from the release of immunosuppressive factors secreted by the glioma cells; 2) 
treatment of glioma patients with immune compromising drugs like steroids and 
hydantoins; 3) the lack of specific tumor antigens; 4) the failure of glioma cells to present 
antigen; and 5) a lack of professional antigen presenting cells (APes) in the brain. 
The reported incidence of brain tumor is on the rise, although, early detection by 
Magnetic Resonance Imaging (MRI) and other advanced clinical diagnostic procedures 
may account for the apparent increase. Imaging technologies now make it possible to 
detect very small tumors before they cause clinical symptoms. Worldwide, the incidence 
of all forms of primary brain tumors ranges from 4.2 to 12.8 per 100,000 (Brewis et at., 
1966 and Liebowitz and Atler,1969). Baily (1948) and Zulch and Borck (1965) reported 
that medulloblastoma, cellular astrocytoma, ependymoma, pineal region tumor, teratoma 
and craniopharyngioma all showed peak incidence in childhood and young adults (less 
than 20 years of age). Tumors of older adults frequently involve the cerebral hemispheres 
and include astrocytoma, oligodendroglioma, meningioma, pituitary adenoma, neurinoma 
of the cerebellopontine angle and astrocytoma of the cerebellum, with GBM and 
metastatic tumors most commonly found in people between 50 and 60 years of age 
(Bruner, 1994). 
Malignant gliomas have been abJe to evade aggressive conventional forms of 
therapy; such as, surgery, radiation and chemotherapy, despite the increase in the 
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understanding of the biology of tumors. Most surgically removed malignancies will recur 
locally, but about 5% of the time they will recur at a different site within the brain. A 
tumor, once established, usually continues to outstrip the inhibitory action of any 
immuno-biological defense mechanisms against it. 
Reasons for this weak response by the host are: 1) the central immune system of 
those who develop tumor may be impaired so that an effective immune response can not 
be mounted against the tumor; 2) changes in the surface p roteins of the tumor cells may 
block the immune response with peripheral sensitization of lymphocytes; 3) secretion of 
immunosuppressive factors, such as transforming growth factor-f) (TGF-f)), which 
decreases the ability of the host's immuno-surveillance system to recognize and attack 
the tumor; 4) the striking heterogeneity that characterizes GEM., in that there is no known 
tumor-specific antigen or receptor that is common (Debinski et al., 1999) and 5) extreme 
dissemination of glioma cells within the brain due to passive perivascular cell placement 
mediated by the cerebro-spinal fluid (CSF) and an active cell migration (Pedersen et a!., 
1995). 
The significance and completion of this study was that despite the great hope of 
immunotherapy, cancer cells are masters of deceit and disguise that can readily alter 
themselves to evade immunologic recognition and attack. Because the race is between 
immune control and escape, the best strategies to combat cancer will need to attack it on 
several fronts. Opportunities that have been explored include constructing vaccines that 
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combine a variety of antigens (polyvalent vaccines); testing how well antibody and 
vaccine-based approaches work together; and combining nonspecific and specific 
immunotherapies and other cancer therapies. Many promising opportunities wait to be 
studied. Perhaps these therapies will yield cures - the universal objective of cancer 
researchers. Developing therapies that can change the nature of cancer from a progressive 
disease to one that may be controlled throughout life may be a more achievable and 
realistic aim. 
A d aptive Versus Innate Immune Respo nse 
The immune system has evolved into two parts: one that is responsible for an 
immediately responding, non-specific response called the "innate immune response" and 
one that depends specifically on the immune challenge and requires plasticity and 
memory called the "adaptive or acquired immune system" (Becher et ai., 2000). 
Leukocytes are responsible for both adaptive and innate immunity. In 1997, Medzhitov 
and Janeway made it clear that these two systems are not separate, but are functionally 
intertwined and the actions of one has a profound effect on the other. 
The innate immune system allows recognition of foreign material or matter via 
germ-line encoded pattern recognition via specific antigen-receptors generated by 
somatic recombination. Adaptive immune responses depend upon lymphocytes. B and T 
lymphocytes are the cellular members of the adaptive immune system. These are 
generated in primary lymphoid tissues- bone marrow and thymus. They populate the 
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secondary lymphoid structures- lymph nodes and spleen. These lymphocytes provide life­
long immunity that can follow exposure to disease or vaccination. 
Granulocytes are the first cells that migrate into tissues in response to invading 
pathogens. Granulocytes are a diverse collection of cells that include eosinophils, mast 
celis, basophils and polymOIphonuclear (PMN) leukocytes- neutrophils. Their principal 
role in inflammatory and immune responses has long been thought to be the phagocytosis 
and killing of bacteria, via the generation of reactive oxygen intermediates and the release 
of lytic enzymes stored in granules (Cassatella, 1995).These cells are referred to as 
granulocytes because they contain prominent cytoplasmic granules. Non-granular cells of 
the innate immune response are monocytes and macrophages. Together, the adaptive and 
innate immune systems provide an effective defense system 
Primary and Second ary Organs: 
The cellular members of the adaptive immune system are Band T lymphocytes. 
These cells are generated in bone marrow and thymus and recirculate in spleen and 
lymph node. They survey other organs through the blood and lymphatic systems in search 
of pathogens and/or foreign substances. Since the immune privilege of the CNS is not 
complete, Wekerle et al. (1987), suggested there is a certain degree of ongoing traffic of 
i mmune cells and molecules through the blood-brain barrier (BBB), and transport to 
regional lymph nodes. Due to this immune surveillance, trafficking in the neuro-immune 
network is initiated in the CNS. 
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Bone Marrow: Primary Lymphoid Tissue 
The bone marrow is soft tissue found within the bones of the skeleton of the body 
and is the site of production of new blood cells or hematopoiesis. The various cell types it 
contains are adipocytes, stromal cells, and blood fonning cells (hematopoietic tissue). 
The bone marrow is the location of stem cells of all blood elements, including the 
precursors of lymphoid cells. These stem cells- multipotent hematolymphomyeloid stem 
cells and their progeny - are organized into groups within fatty tissue. The various cell 
lines found in the bone marrow are red blood cellslerythroblasts, 
macropbages/monoblasts, platelets/megakaryocytes, polymorphonuclear 
leukocytes/myeloblasts, and lymphocytes/lymphoblasts. 
The bone marrow is not the site of reaction with, or response to Ag. Marrow 
lymphocytes circulate from the marrow to other lymphoid organs and differentiate into 
lymphocytes capable of immune function. Cells originating in the bone marrow populate 
the thymus where they may differentiate into T cells, whereas B lymphocytes 
differentiate in the secondary lymphoid tissue. 
Thymus: Primary Lymphoid Organ 
Thymic structural heterogeneity derives from its embryological origins - its 
development requires significant input from all three germ layers. The epithelium is 
derived from the 3rt! and/or 4th pharyngeal pouch endoderm. Phenotypic studies have 
shown that the first epithelium to develop is cortical, followed by small medullary islets 
which expand in synchrony with the appearance of mature T celis, and subsequently the 
capsule toward the end of embryogenesis or even neonatal period (Boyd et al., 1993). 
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The thymus is encapsulated by a thick outer layer of connective tissue and a thin 
connective tissue layer directly overlying the cortex. The subcapsular sinus separates 
these layers. Fibroblasts and type 1 collagen-rich trabeculae penetrate the cortex and 
terminate at the cortico-medullary junction (Boyd et a!., 1993). These trabeculae lobulate 
the thymus and provide a structural link with the inner medulla. Trabeculae contain 
fibroblasts, adipocytes, eosinophils, neutrophils, plasma celis, mast celis, macrophages 
and granulocytes and are well vascularized and innervated. Lining the subcapsule and 
trabeculae is a basement membrane supporting a flattened epithelium. This creates a 
barrier between the external and internal thymic environments. Boyd (1993) describes 
the internal base of the trabeculae as having perivasculature spaces which constitute the 
blood-thymus barrier. 
The subcapsular/subtrabecular region is one of the most important in the thymus. 
It initiates thymopoiesis and produces thymic hormones (Kendall, 1991). Determinates 
specific for this region have been identified and the region labeled by Thy. 1 in humans 
(Boyd, 1993). 
The thymic cortex can be differentiated from the medulla because the 
lymphocytes are much more closely packed in the cortex. There are no afferent 
lymphatics in the thymus. The cortex is an area of active proliferation., with turnover of 
cells every 3 or 4 days (Miller, 1993). According to Boyd (1993) and Miller (1993),1% 
of the lymphocytes produced leave the thymus via blood vessels; the other 99% are 
destroyed locally via apoptosis. 
In the cortex. many thymocytes are located within vacuolar membranes of large 
epithelial cells known as thymic nurse cells. These 1ymphoepithelial cell complexes 
provide a close association between intact, actively dividing thymocytes and large 
cytoplasmic vacuoles of the epithelial nurse cells. It is within the thymic nurse cells, 
which are epithelial reticular cells, that thymocytes may learn to identify self from 
nonself. Prothymocytes arriving from the bone marrow develop receptors for major 
histocompatibility complex (MHC) markers. At the time of positive selection, the 
prothymocyte expresses both the CD4 and CD8 co-receptor molecules. At the end of the 
selection process, mature thymocytes ready for export to the periphery express only one 
of these two receptors. CD8 thymocytes have receptor for Class I MHC molecules. T 
cells that express CD8 are programmed to become cytotoxic effector cells. CD4 
thymocytes have receptors that recognize peptides bound to selfMHC Class II 
molecules. CD4+ T cells are programmed to become cytokine-secreting cells. Thus, 
positive selection also determines the cell-surface phenotype and functional potential of 
the mature T cell, selecting the co-receptor that it requires for efficient Ag recognition 
and programming it for appropriate functional differentiation upon activation of the 
immune response. 
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High affmity self-reactive thymocytes, that might give rise to autoimmune 
disease, are removed by negative selection at the junction of the medulla after reaction 
with thymic dendritic cells which are rich in MHC molecules. The surviving cells are 
then ready for release into the circulation and for further maturation in the peripheral 
lymphoid organs. 
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The medullary epithelium, represented by Hassal's corpusles, express different 
phenotypes as differentiation from medullary epitheloid reticular cells to endocrine 
epithelium where mature Hassal's corpuscles occur. Thymocytes also show 
differentiation-related phenotypic changes from cortex to medulla as defined by 
phenotypic markers identified by monoclonal antibodies. The subcapsular cortex 
contains the least mature thymocytes. In the deep cortex more differentiated thymocytes 
are seen. Maturation to even more mature thymocytes occurs in the medulla. Further 
differentiation occurs after the cells leave the thymus and reach peripheral lymphoid 
organs. 
Lymph Nodes: Secondary Lymphoid Organs 
Lymph nodes (LNs) are small organs occurring in series along the course of 
lymphatic vessels. Their parenchyma consists of a highly organized accumulation of 
lymphoid tissue. Cells of tbis tissue recognize antigenic materials in the lymph that 
percolates through the node. This induces a specific immune response. LNs are rich in 
macro phages, which clear the lymph of undesirable cells, invading microorganisms, and 
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other particulate marter. 
LNs are located in areas of lymphatic drainage in the body and serve as filters for 
tissue fluid in lymphatic vessels. Classically, the organ is divided into the inner zone, the 
medulla, surrounded by the outer zone, the cortex. In the classic concept of the LN 
architecture, the LN comprises a superficial cortex containing lymphoid follicles 
alternating with interfollicular regions, a deep cortex or paracortex and a medulla (van 
den Cord et aI., 1985). There are three kinds of spaces in each of these regions: 1) an 
intralymphatic space; 2) an intravascular space; 3) and an extravascular space or 
interstitium. Both the vascular endothelium and lymphatic endothelium are specialized in 
different regions of the node (Fossum and Ford, 1985). 
They point out that the intercalation ofLNs in the lymph stream serves a dual 
purpose in the defense of the body. First, phagocytes residing within the LNs ingest 
invading organisms arriving via the lymph and thus reduce the load of organisms 
reaching the blood stream. Secondly, according to Gowans and Knight (1964), LNs are 
ideally located as control posts for the immune system This is because lymph draining 
wide areas is funnelled through their narrow confines. This allows the surveillance 
function of the immune system to be concentrated in small LN volumes. This results in 
patrolling lymphocytes continuously entering LNs from the blood stream by crossing the 
wall of the specialized postcappillary venules (Gowans and Knight, 1 964), to leave again 
within a few hours in efferent lymph if they fail to meet an Ag they recognize. Studies by 
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Herman et aI., (1972), Cahill et aZ. (1976), Hay and Hobbs (1977), and Drayson et aI. ,  
(1981) found that after local antigenic stimulation, specific lymphocytes are concentrated 
in the regional LNs. This is due to a combination of an enhanced rate of lymphocyte 
traffic into the nodes associated with increased blood flow and selective retention of Ag­
specific lymphocytes within the nodes. The recruitment of specific lymphocytes from a 
large recirculating pool serves to amplify the immune response. The chances of a 
successful encounter between Ag and specific lymphocytes are, according to Unanue et 
aZ . (1984), further increased by the strategic position of APCs in the middle of 
lymphocyte traffic areas within LN s. 
APCs function primarily by displaying Ag in highly immunogenic forms on their 
surfaces. Ag, according to Mandel et aI., (1984), can also be retained for prolonged 
periods on the surface of follicular dendritic cells within the nodes, whereby repeated 
stimulation ofB lymphocytes occurs in the absence of renewed external challenge. This 
generates immunological memory in B cells over an extended period of time. In 
summary, LNs are the sites of confluence of lymph-borne Ag and blood-borne 
lymphocytes. 
SpZeen: Secondary Lymphoid Organ 
Like the LN, the human spleen is a highly compartmentalized organ. Each 
compartment has its own structure, cell population, and functions. The lymphoid follicles 
and the surrounding lymphoid tissue is called white pulp and the sinusoidal area, which 
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usually contains large numbers of red blood cells, is called the red pulp. A zone of 
densely packed lymphocytes surrounding the central arteriole contains T cells, while B 
cells are found surrounding the germinal center. The mantel surrounding germinal centers 
is composed mainly ofB cells, but also T cells believed to be pushed aside from the B­
cell zone by formation of the germinal center. In humans, there are two main functions: 
production of immunological responses against blood-borne Ags and removal of 
particulate matter and aged or defective blood cells, particularly erythrocytes, from the 
circulation (van Krieken and Velde, 1988). 
Cells of the Amnastic Immune Response: 
T Lymphocytes 
T lymphocytes are not able to recognize free Ag but rather their recognition of 
Ags involves an interaction of the T cell receptor (TCR) with fragments of Ag bound to 
e ither class I or class II major histocompatibility complex (MHC) molecules on the 
surface of APe. Cells that are capable of processing Ags and displaying them on their 
surfaces are referred to as antigen presenting cells (APC). As defined by Fabry and Hart, 
( 1993), all of the events that take place between uptake of Ag and T cell recognition are 
called "Ag presentation". This Ag presentation is dependent on specific and non-specific 
signals. Ag-specific T cells are activated through their clonaliy restricted T cell receptor 
(TCR) complex. Class I restricted T cells show almost exclusively CD8+ 
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cytolytic/suppressor phenotypes, whereas Class II-restricted cells are CD4+ T-helper cells 
(Fabry et al., 1 993). The TCR is a disulfide-linked heterodimer made up of two chains, 
either a and p chains on the aj3 T cells or y and 0 chains on the yo T cells (Allison et al., 
1 987; Raulet et aI., 1 989). The a� chains function together as Ag receptors on mature ap 
T cells. The precisely defined TCR repertoire is formed during thymic development using 
four different gene segments: the variable (V), diversity CD), joining (1), and constant (C) 
regions. These gene segments come together in random fashion and are expressed as a 
single protein molecule containing the a (VaJaCa) and P(Vj3DPJj3CP) chains (van 
Ewijk, 1 991). Upon leaving the thymic environment, the individual mature cells have 
specificity. This specificity is determined by the variable regions of the ap TCR a and p 
chains which form a combining site that has contact residues for both the MHC-bound 
peptide and the MHC molecule (Kappler et al., 1 987; von Boehmer et aI., 1 989 and 
Fowlkes et al., 1 989). 
Secondary signals are also generated as result ofthe TCR-Ag-MHC interaction 
and are transmitted through CD3. CD3 is a multimolecular complex expressed in a 
noncovalent association with the TCR on the surface of all mature T cells. 1be CD3 
complex includes invariant chains y, �, () and C (Clevers et aI., 1 988). An example of a 
secondary signal is phosphoinositide-specific phospholipase C, which mediates 
breakdown of inositol phospholipids, in turn giving rise to two second messengers, 
inositol phosphates and diacylglycerol. According to Fabry et al., ( 1993) the resulting 
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increase in intracellular Ca2+ concentration and translocation of protein kinase C (PKC) to 
the plasma membrane are thought to initiate the cascade of biochemical events leading to 
activation ofT cell effector functions and clonal expansion. The consequences ofT cell 
activation are the presentation of Ag and stimulation of the T cells. This results in 
lymphokine gene transcription, translation, and secretion. This in turn influences 
activation, proliferation, and differentiation ofT cells, B cells, and a variety of other cell 
types in the microenvironment of the T cell response. 
Several different APCs play a major role in T-cell activation. These include 
mononuclear phagocytes (monocytes, macrophages), B lymphocytes, and Langerhans-
dendritic cells. These cells are referred to as "professional" APC. They generally express 
MHC Class II molecules constitutively, which can be further up-regulated with 
cytokines. They can also express several co stimulatory molecules such as IFN-)' and 
Class II on B cells, and increased Class II on macrophages and dendritic cells. 
T LymphoCYtes of Both the Naive and the Memory Phenotype: 
A fundamental feature of vertebrate immune systems is immunological memory 
(Mackay, 1 99 1 ). The term "immunological memory" is used to describe the rapid and 
enhanced immune responses to specific pathogens that have been previously 
encountered. Memory is thought to be a feature among long-lived cells and this can be 
years later and produce a faster and larger response. These cells are also present at higher 
frequencies compared to their nalve precursors through clonal expansion (Mackay, 1 99 1 ) .  
A systemic immune protection is provided by these cells as they are distributed and 
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recirculate through the body. Mackay suggested that a major advance in understanding 
memory has been the characterization of numerous cell surface molecules that distinguish 
memory T cells from naive T cells. 
T cell subsets were first identified by a CD45 monoclonal Ab (mAb) in 1981  
(Sanders et  ai., 1 98 8). Moriority, ( 1985), Rose et  ai. ( 1985), and Tedder et  ai. (1 985), 
several years later independently reported functional characterization of these subsets or 
their association with a particular disease (Sanders et ai., 1 988). The CDw29 mAb 4B4 
marker was identified by Morimoto and coworkers, ( 1985). The CDw29 mAb 4B4 
showed increased binding to the same T cell subset that had decreased CD45 expression 
(Morimoto, et aI., 1985,  Smith et al., 1 986, Sanders et al., 1988; Budd et al., 1 987). 
Subsequently, additional mAbs were identified that distinguished T cell subsets sharing 
functional attributes of the CD45-high and CD w29-high subsets. Two flow cytometry 
was used to give a direct comparison of markers. These data showed that these differed in 
expression of CD45 and CDw29, but also that of five additional surface markers 
(Sanders, 1988; Me, 1 988; Makgoba, 1988 and Sharrow, et aI., 1 98 8) .  These markers are 
the most useful for enumerating or sorting T cell subsets. 
It was thought that these subsets represented different lineages ofT cells, e.g. 
CD4+ and CD8+. Tedder and coworkers, ( 1988) instead proposed that they consisted of 
cells at different maturational stages. According to Saunders et ai., ( 1 988) this theory is 
now supported by the resuhs from many laboratories that have shown that the peripheral 
blood T cells of the CD45R- high subset convert to the CDw29-high subset, but 
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conversion in the opposite direction has not been reported.. Thus, T cell expression of 
many surface molecules changes with T cell activation. These investigators singled out 
six aspects of functional differences between subsets: 1 )  differentiation into memory cells 
is accompanied by biochemical changes which make them more sensitive to CD2 and 
CD3 receptor-mediated activation and may result in enhanced responsiveness to low 
concentrations of foreign Ag; 2) activation of memory cells leads to secretion of large 
amounts ofIFN-y and Interleukin-3 (IL-3), while activation of naive cells results in little 
or no secretion. In contrast, naive and memory cells secrete comparable amounts of IL-2 
in response to PHA stimulation; 3) memory cells differ from naive ones in their use of 
accessory molecules CD4 and CD8. It is suggested that this may reflect higher affinity­
specific receptors, enhanced signal transduction via CD3 or other biochemical changes 
affecting the function of accessory molecules in memory cells; 4) naive cells proliferate 
preferentially in response to certain immunologic stimuli such as phytohemrnaglobin 
(PHA) and to autologous non-T cells. These cells are preferentially responsive to 
particular conditions of CD2 and CD3-mediated stimulation, naive cells can be activated 
preferentially when other signals are delivered; 5) the ability to mediate suppression is 
not unique to naive cells because memory cells can also induce the suppression of Ag­
specific B-cell responses; and 6) memory cells are slightly larger than naive cells. This 
cell size increases with activation and after memory cells have undergone prior 
activation. In summary, immunological memory' s  main feature is that it is specific, long-
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term and systemic. An immune response in any one site will lead to a memory-type 
response upon challenge in another tissue. This is achieved through the dissemination and 
recirculation of memory cells throughout the body. 
Westermann ( 1997) stated that in humans, approximately 5x101 1  lymphocytes 
leave the blood each day, migrate into the tissues and return into the blood in their 
continuous search for specific Ag. T cells recirculate through the body by one of two 
basic pathways: 1) the vast majority recirculate by crossing high endothelial venules 
(HEV), and 2) after about1 8-20 hours residency in a LN, and leave through the efferent 
lymphatic duct (MacKay, 1991). T lymphocytes may also leave the blood in peripheral 
vascular beds, particularly within inflammatory lesions. Local LNs receive these 
draining cells via the afferent lymphatic vessels. CD4+ T cells of both the naive and the 
memory phenotype enter LNs and Peyer's Patches via HEV. However, within the tissue 
their migratory behavior differs. About 1 0% of these lymphocytes enter LN and Peyer's 
Patches (PP) via HEV and leave via the efferent lymphatic vessel This leaves over 90% 
of the lymphoeytes migrating through these organs (Fossum and Ford, 1985). Due to the 
specialized environment of LN and PP, concentrated Ag is directly situated in the path of 
recirculating lymphocytes. This optimizes the chance of specific T cells finding their 
cognate Ag (Fossum and Ford, 1985). 
Mackay, ( 199 1), mentioned a study in which sheep were used to investigate these 
two compartments of recirculating cells. The study revealed that there is a striking bias in 
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the class ofT cells that take these two migration pathways. These suggested migration 
pathways are : 1) T cells in peripheral afferent lymph, draining tissue such as th� skin, 
were entirely of the memory type; and 2) T cells within efferent lymph; the vast majority 
of which originate from the blood via HEV, were overwhelmingly of the naive T-cell 
type. The study demonstrated that nalve T cells entered LNs by crossing HEY. Memory 
T cells entered tissues and drained to a regional LN through afferent lymphatics. The 
efferent lymph also was used by both naive and mT cells to leave the LNs and return to 
the blood. Once they left by the efferent lymphatics, they repeated their respective 
recirculation pathways. 
Phagocytes in Gliomas: 
Macrophages: 
The monocyte-macrophage system is a network of specialized phagocytic cells 
widely scattered throughout the body. These cells include peripheral blood monocytes, 
dendritic cells, Kupffer cells of the liver, macrophages of LNs and spleen, fixed 
macrophages of other tissues, and CNS microglia (Lorusso and Rossi, 1 997). Available 
evidence suggests that peripheral blood monocytes originate from bone marrow 
precursors and that tissue macrophages, including brain macrophages, are derived from 
circulating monocytes that migrate into tissues where they become resident (Kinney and 
Armstrong, 1 997). 
20 
Bone marrow precursors therefore maintain the pool of peripheral blood 
monocytes and tissue macrophages. Fujita et al., ( 1 976) and Oehmichen and Huber, 
( 1 976), indicated that some of the CNS macrophages derive from resident microglia. del 
Rio-Hortega recognized microglia in 1 932 by means of silver carbonate impregnation 
(del Rio-Hortega, 1 9 1 9  and 1 932). Microglia, originating from embryonic mesenchyme, 
distribute to the CNS white and gray matter where they become resident macrophages, 
and comprise between 5% and 20% of the total glial population (Lawson et a/., 1 991) .  
As mentioned, monocytes originate from non-lymphoid precursors within bone 
marrow and circulate in the peripheral blood with a half-life of 1 to 3 days (Haynes and 
Denning, 1 993). Monocytes leave the circulation by margination into the connective 
tissue. The maturation and differentiation of monocytes into macrophages is influenced 
by various processes including chemotactic factors (Mauri et ai, 1 987;  Verghese and 
Snyderman, 1 989). Lymphocytes (Ball.'Wi.ll, 1 989), bacterial endotoxins (Levy and Cole, 
1 989), plasma proteins (Ross et al., 1 989) and cell surfaces are such examples (Berton 
and Gordon, 1 983). 
Macrophages bearing MHC Class II receptors and Interleukin-2 receptors (ll.-2R) 
participate in the immune process as APCs. Other immune mechanisms include antibody­
dependent cell-mediated cytotoxicity (ADCC) through the binding with Fc receptors of 
killer cells, and non-MHC specific restricted cytotoxicity (Tada and de Triboleta, 1 993 .) 
Ag presentation by macrophages is a process involving two signals. Signal 1 is 
Ag-specific and originates from the binding of the APC receptor to the peptide-MHC 
complex. Signal 2 is Ag-nonspecific and is triggered by the B7 molecule exclusively 
expressed by APCs, which interacts with CD28 expressed on Th cells. Signal 1 ,  in the 
absence of Signal 2, results in T cell inactivation or "T cell anergy". Macrophages may 
also be stimulated to release lysosomal enzymes following interaction with antigen-
antibody complexes (Ferreri et ai, 1 986) and with lymphokines, e.g. IFN-y, and to 
operate selective targeted-phagocytosis and opsonin-mediated phagocytosis (Berry and 
Butt, 1 997). 
N eutrophils: 
Neutrophils, also known as polymorphonuclear (PMN) cells, are terminally 
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differentiated, short lived cells, and incapable of proliferation. PMNs are the most 
common type ofleukocyte in blood, but not in rats, and constitute 40-70% of the 
circulating nucleated cells (Wheater et al., 1 993). Histologically, the prominent features 
of the PMN cells are (1)  their highly lobulated nucleus; when mature, there are usually 
five lobes connected by fine strands of nuclear material; (2) their high motility and 
phagocytic activity; and (3) their principal function in the acute inflammatory response to 
tissue injury where they ingest and destroy damaged tissue and invading micro-
organisms, particularly bacteria (Wheater et al., 1 993). 
The cytoplasm of neutrophils is lightly stippled with azurophilic granules which 
represent large lysosomes. These are often referred to as primary granules that appear 
during neutrophil maturation. These granules contain characteristic acid hydro lases but 
also a number of bacteriocidal agents including myeloperoxidase. 
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To be cytotoxic after antigenic activation, neutropbils require stimulation by 
complement factors, leukotrienes, or other cytokines whereas lymphocytes become 
cytotoxic or antibody-producing after antigenic challenge. Experimentally, there are data 
that neutrophil infiltration into gliomas can occur in response to cytokines. Wright and 
Merchant ( 1 997) showed a marked infiltration of leukocytes (mostly neutropbils) in the 
RT -2 rat glioma model after an IC injection of tumor necrosis factor-a (TNF-a). 
Fossati et al., ( 1 999), reported on the results of an analysis of infiltration of 
neutropbils in human gliomas. Sections of tissue were stained for CD 1 5+ and 
myeloperoxidase + cells. Their analyses showed that over 70% of all gliomas analyzed 
bad significant neutrophil infiltration and there was a marked and significant correlation 
between tumor grade and the extent of the neutrophil infiltration. Of the low grade 
tumors, only 40 to 50% had significant infiltration; however, in GBM over 85% of the 
samples analyzed had significant infiltration. The presence of neutrophils in areas of 
necrosis suggests that these infihrating cells may play an important role in glioma 
pathology; i.e., they could be responding to necrotic lesions or could be promoting cell 
death and destruction. 
A mounting body of evidence indicates that PMN survival can be extended 
following exposure to rnicroenvironmental signals in infection and immunity. These 
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signals include lipopolysaccharide (LPS), IL-l �, TNF-a, interleukin- 6 (IL-6), IFN-y, 
granulocyte-colony stimulating factor (G-CSF), and granulocyte macrophage-colony 
stimulating factor (GM-CSF) (Cassatella, 1 995). Neutrophils should be considered not 
only as active and central elements of the inflammatory response, but also as cells that 
through cytokine secretion, may significantly illfluence the direction and evolution of the 
immune response. 
G ranulocytes: 
Mast Cells: 
Mast cells (MCs) occur in many organs and tissues, including the CNS of several 
species, including humans (Ibrahim, 1 974). MCs are highly granulated connective tissue 
cells that store and produce a number of inflammatory mediators (Compton, 1 952). 
Neumann, 1 890, identified them over a century ago in brain infarcts and at the edge of 
multiple sclerosis. According to Hebda et at., 1 993, tissue MCs are normally distributed 
widely throughout different organs such as the skin, upper and lower respiratory tract and 
gastrointestinal tract. In most issues, including the skin, MCs are generally concentrated 
around small blood vessels, lymphatics and nerves (Eady et aI., 1 979). Specialized 
intercellular contact between mast cells and fibroblasts have also been documented. In 
addition to their cytoplasmic projections, mast cells have the expected normal 
comp liment of cellular organelles (Greenberg and Burnstock, 1 983). However, the most 
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characteristic morphological feature of these cells is the presence of numerous 
cytoplasmic granules which are individually enclosed in a bilayered membrane ( Craig et 
aI., 1 988 ). 
Two types of granular cells are seen and are referred to as Type I cells and Type 
IT cells (Ibrahim, 1 974). Both types have been seen in the CNS of the mouse, rat, hamster 
and cat while the CNS of the guinea pig, rabbit, dog, monkey and man contained almost 
exclusively Type IT cells (Ibrahim, 1 974). Type I cells in the adult were generally oval or 
rounded with a central oval or rounded nuclei. Ibrahim, ( 1 974), describes these cells as 
containing round and uniform granules, about 0.2-0.5 urn in d iameter which often 
masked nuclear detail. By electron microscopy the cells were seen embedded in an 
extension of the basement membrane system of the blood vessel and had pseudopod-like 
surface extensions (Ibrahim, 1 974). 
Type II cells of the rodents and the monkey, and some of those of the dog and 
adult human were regular oval or spindle-shaped (Ibrahim, 1 974). By electron 
microscopy, Ibrahim, 1 974, has shown that these cells had many features in common 
with Type I cells, the main differences being the larger and variable granule size and the 
greater homogeneity and darkness of the granules, probably reflecting their greater lipid 
content. 
Regarding distribution of these cells within the CNS parenchyma both types of 
cells were located around arterioles and venules but not around capillaries (Hebda et aL, 
1 993). No cells were normally seen at a distance from a blood vessel except in the 
leptomeninges, in the nerve fiber layer of the olfactory bulbs and in the choroid fissures 
and plexuses. 
Type I cells are scanty in the mouse but more plentiful in the adult rat. MCs, 
according to Gruber et aI., 1 995, are often found near blood vessels in the resting state 
and it is widely recognized that mast cells associate with newly forming micro-
vasculature. Thus, early accumulation of masts cells locally at a tissue site appears to 
potentiate vessel growth. 
Type II cells were numerically proportional to the richness of regional blood 
supply. Gray matter, because of its wealth in such vessels, contained more cells than did 
white matter (Ibrahim, 1 973). For the same reason the cerebral cortex contained more 
cells than most other grey matter areas. 
Mast cells (MC) are involved in infammatory and hypersensitivity reactions (Galli 
et al., 1 984) and occur in many peripheral tissues, in perivascular regions, in close 
apposition to innervating sensory or autonomic nerve fibers (Bienenstock et aI., 1 987) 
and also within the peripheral nervous system and CNS (Johnson, D. and Krenger, W., 
1 992). As suggested by Leon et aI., 1 994, neurons and immunological mediators such as 
neuropeptides or immunoglobulin E (lgE) can affect the state of mast cell activation. 
According to Ratzlaff, R et al., ( 1 992) secretory products of activated MCs can stimulate 
or facilitate axon reflexes, thereby inducing positive feedback loops. Activated MCs also 
secrete a wide array of pluripotent cytokines and other inflammatory mediators and 
therefore, may act as bidirectional carriers of information between the nervous and 
immune systems (Leon, A et aI., 1 994). 
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MCs are also classically associated with allergic response and are secretory cells found 
primarily in connective tissue such as the lungs and skin (Dimitriadou., 1 990). These cells 
synthesize and secrete numerous powerful mediators such as : endorphins, histamine, 
kinins, leukotrienes, prostaglandins, serotonin, vasoactive intestinal peptide, proteolytic 
enzymes and phospholipases ( Baloyannis, S. and Theoharides, T., 1992). 
Bienenstock, J. et ai., ( 1 987) and others report that a close relationship exists 
between the nervous system and the immune system. This could explain such 
pathological conditions as inflammatory processes, asthma., vascular headaches, certain 
tumors, and autoimmune diseases such as multiple sclerosis. All of these cases appear to 
be associated with an increase in the numbers of MC, which can be stimulated to secrete 
various neuropeptides and neurotransmitters such as acetylcholine (Fantozzi R. et ai, 
1 978). 
The close proximity between the cerebral MC and the cerebrovascular organs 
suggests that these cells could have important functions in controlling the integrity of the 
blood-brain barrier. Secretion of vasoactive molecules could make this barrier permeable 
to blood lymphocytes or pathogenic agents. 
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CD251IL-2 Recepto r: 
An important requirement for proliferation of mitogen or Ag-stimulated 
lymphocytes is not only the production of IL-2, but also the interaction of this cytokine 
with its receptor. The IL-2R is formed on the cell membrane by the noncovalent 
interaction of two polypeptide chains (Greene, 1 988; Wang et aI. , 1 987). The 55Kd 
protein (T AC Ag, CD25) represents one of these receptor proteins which associates with 
a 70Kd protein to form the functional high affinity IL-2R . The IL-2R subunit, IL-2R a 
(p55, Tac antigen, CD25), is a protein of 251 amino acids (Minami et al., 1 992 and 
1 993). The gene for human IL-2R a is located as a single copy on chromosome l Op/ 1 4-15 
(Leonard et al., 1984 and Kuziel and Greene, 1991). Post-translational processing of IL-
2R a involves glycosylation, sulfation and phosphorylation, resulting in its final MW of 
55Kd (Hanisch and Quirion, 1 996). Hanisch and Quirion also reported that IL-2Ra has a 
low affinity, whereas IL-2R a in association with IL-R �, or in the trimeric complex a�y, 
contributes to the high-affinity binding sites for IL-2 with Kd values in the range of 1 0.10 
and 1 0-1 1  M. Expression of IL-2R a in T cells, B cells and monocytes depends on 
induction by certain stimuli such as, Ag, IL- l ,  TNF �, mitogen or by IL-2 itself (Arima et 
al. ,1 992; Ballard et aI., 1 989; Hatakeyama and Ta.nl.,cyuchi, 1 99 1 ). 
As mentioned, the effects of IL-2 on the activation of its target cells are mediated 
through specific cell-surface receptors.  The IL-2 receptor comprises at least three 
subunits encoded by different genes. The first component to be identified, IL-2R a, is a 55 
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kDa protein that binds IL-2 with a Kd of about 1 0  nm and shares homology with the Q­
chain of the IL- 1 5  receptor (Theze et al., 1 996). The other identified subunits are IL-2R� 
and IL-2Ry. IL-2� .is a 75 kDa protein containing a large intra-cytoplasmic domain of 
286 amino acids. IL-2� .is shared with IL- 1 5  whereas IL-2Ry .is a 64 kDa protein that 
also participates in the formation of the IL-4, IL-7, IL-9 and IL-15 receptors (Theze et al, 
1 996). This chain .is also critical for signal transduction via JAK-3. 
The cytokine, IL-2, has multiple immuno-regulatory functions and biological 
properties not only related to T cells. Hanisch et al., ( 1 996) provided the following 
evidence that suggested that IL-2 .is also a modulator of neural and neuroendocrine 
function: 1 )  extremely potent effects of IL-2 on neuronal cells was discovered that 
included activities related to cell growth and survival, transmitter and hormone release, 
modulation of bioelectric activities; 2) IL-2 may be involved in the regulation of sleep 
and arousal, memory function, locomotion and modulation of the neuroendocrine axis; 3) 
the concept that IL-2 could act as a neuroregulatory cytokine has been supported by 
reports on the presence in rodent and human brain tissues ofIL-2-like immunoreactivity, 
IL-2-like mRNA, IL-2 binding sites, IL-2 Rex and � chain mRNA immunoreactivity and 
4) IL-2 and/or IL-2R molecules mainly localize to the frontal cortex., septum, striatum, 
hippocampal formation, hypothalamus, locus cereleus, cerebellum, the pituitary and fiber 
tracts, such as corpus callosum, where they are likely expressed by neuronal and glial 
cells. 
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Elliot et al. ( 1 992) reported that T cells, obtained from patients harboring 
malignant gliomas, exhibited a profOlllld decrease in mitogen-induced proliferation. This 
was presumed to be a consequence of a failure of these cells to secrete normal amounts of 
IL-2 and express the IL-2R. They and others (Fontana et al., 1 982; 1 984) report that 
glioma cells are capable of diminishing lymphocyte function and may be responsible for 
the marked inhibition of immune function in these patients. The finding that glioma cells 
secret factor( s) that suppress the function of lymphocytes from normal subjects supports 
this hypothesis (Roszman et al. , 1 987). 
Blood Brain Barrier: 
Normal: 
The most notable morphological difference between the CNS and tissues of other 
systems is the existence of a barrier that separates the CNS tissue from the blood, thereby 
preserving the CNS protected environment. The blood-brain barrier (BBB) was once 
considered to be a single membrane. However, it actually consists of luminal plasma 
membranes, cytosol and abluminal membranes of the endothelial cells. Because of 
morphological difference, for many years it was believed that the brain was an "immuno­
privileged" site, possessing few if any immune elements (Fossati et aI., 1 999). Wahl et 
al., ( 1 988) described the morphological substrate of the BBB in cerebral vessels as a 
continuous layer of endothelial cells with tight junctions and no or minimal vesicular 
transport. He presented functional characteristics of the BBB as: a) low diffusional 
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permeability for compounds, b) low hydraulic conductivity, c) high reflection coefficient, 
and high electrical resistance. The consensus of a limited BBB was based on the 
following: 1 )  the cerebral capillary endothelial cells that constitute the BBB differ from 
those of the peripheral circulation in that they form extensive tight, impermeable 
junctions between adjoining cells; 2) endothelium is devoid of fenestrations and 
transcapillary channels and express a very low rate of pinocytotic activity; and 3) this 
continuous barrier means that, for all but a few compounds, passage into the brain from 
the circulation is determined by the solutes' lipid solubility (Greenwood, 1 990). 
According to Greenwood (1 990), glucose and the amino acids that are essential nutrients 
to meet the high metabolic demand of the brain are transported across the BBB in 
specific transport systems that facilitate their entry into the brain.. 
The existence of all of these parameters are indicative of low diffusional exchange 
o f  water-soluble solutes and inhibition of the penetration of several mediators by 
enzymatic degradation at the endothelial border (Wahl et a!., 1 988). It is known that 
lipophilic compounds can easily cross the BBB by simple diffusion, while transcellular 
transport of hydrophilic solutes is made possible by facilitated diffusion and active 
transport. These mechanisms, described by Wahl et a!., ( 1 988), permit a highly selective 
exchange between blood and brain and provide an optimally controlled homeostatic 
environment for the brain in a pbysiological state. 
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BBB Under Pathological Conditions: 
In many diseases that affect the brain, the cerebral endothelium plays an active 
part in the disease process with the BBB becoming disrupted. This modification can 
cause a dramatic increase in vascular permeability. Consequences related to these disease 
processes include vasogenic brain edema and possible development of secondary brain 
damage (Greenwood, 1 991) .  
Greenwood ( 1 991 )  postulated that increases in  BBB permeability were associated 
with neoplasia, ischemia, hypertension, dementia, epilepsy, infection, multiple sclerosis, 
experimental allergic encephalomyelitis and trauma. Evidence suggests that the cerebral 
endothelium is under direct influence from the astrocytes (Arthur et al., 1987). The unique 
characteristics of the BBB, therefore, are due to factors released by or present on 
astrocytes ( Beck et al. , 1 984). Both Arthur et al.,( 1 987) and Beck et al., ( 1984) 
considered that in certain pathological conditions it is possible that the influence of the 
astrocyte and its factors are lost. This gives rise to structural changes in the endothelium 
following ischemia For example, both intrinsic and newly formed capillaries are often 
devoid of BBB characteristics and resemble endothelium from peripheral tissue. 
Evidence also suggests that in many diseases of the CNS, mediator substances from 
damaged or activated cells can induce barrier dysfunction. Mei Liu (1988) suggested that 
these vasoactive compounds may originate from a number of different sources - the 
blood, the cells of the CNS or from the endothelial cells themselves. 
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Blood-Borne Mediators: 
Schurer et aI., 1 989 have demonstrated that the blood-borne products of the Jcinin 
and complement system, bradykinin and complement C3a, can increase the permeability 
of the BBB in experimental animals. Similarly, platelets, basophils, macrophages and 
active T lymphocytes are cells of the blood, that according to Schurer et ai. , (1 989), have 
been shown to be a major source of vasoactive compounds. T lymphocytes release 
substances, such as histamine (Dux and Joo, 1 982), serotonin (Olesen, 1 985) and 
leukotrienes (Black and HofI: 1 985) that disrupt the BBB. 
The current study was based on the following rationale. 1) human brain tumors 
progress rapidly and are almost invariably fatale despite combination therapy involving 
surgery, radiation and cyto-reductive drugs. 2) Little success has been achieved 
employing aggressive experimental adjuvant therapy against weakly immunogenic 
human tumors. 3) Activation of lymph node lymphocytes which circulate through the 
blood and enter tumors can be induced by immunization. 
Chapter 2 :  
PRIMARY V ACCINA nON I N  T HE  INTRACRANIAL R T  - 2  GLIOMA MODEL 
Introduction 
Current advances in cell biology, tumor immunology, and molecular biology has 
helped rekindle an interest in tumor vaccines as our understanding of Ag processing and 
presentation has evolved. Livingston ( 1 993) and Schirrmacher ( 1 995) base the 
development of vaccines on three premises: ( l )  the presence of qualitative and 
quantitative differences between tumor cells and nonnal cells; (2) the immune system, 
with its complex assortment of cells and cell products, provides specific and nonspecific 
protection against foreign substances; and (3) the immune system can be "taught" to 
recognize these differences and mediate tumor rejection by specific active immunization 
using these vaccines. Our observations support the hypothesis that a primary vaccine is 
able to provide some protection against RT-2 gliomas. 
The first set of studies began by investigating the survival times of rats that were 
vaccinated in the hind footpads (HFPs) with 4 x l  06 irradiated but viable RT -2 cells. Seven 
days later, the animals received intracerebral (IC) injection of viable RT-2 glioma cells. 
Ten thousand RT-2 cells in S ill of phosphate buffered saline (PBS) were injected over a 
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tlllrty minute period. Subsequently, 30% of the primed animals survived the IC challenge. 
These findings suggested that a 10 vaccination of 4xl 06 cells per HFP provided some 
protection, but there was a 70% failure rate in prolonging survival. 
The second set of studies was designed to ask whether the amount of the 
inoculum ( 4x1 06 irradiated cells versus 8x1 06 irradiated cells) affected survival. Data did 
show that this experiment resulted in significant differences in the rate of survival and/or 
length of survival from Experiment 1 .  
The RT-2 Glioma 
The cell line, RT-2, was provided by Dr. G.y' Gillespie and was derived from a 
glioma induced by the inoculation of the Rous sarcoma virus (Schmidt-Ruppin strain) 
into the brain of neonatal Fischer 344 rats. The RT -2 glioma cells are plastic-adherent 
and maintained in Dulbecco ' s  Modification of Eagle ' s  Media (DMEM) supplemented 
with 5% fetal calf serum (PCS). Their in vitro doubling time is 1 4.5 hours. 
It has been suggested and shown that immunotherapeutic approaches for 
treatment of brain tumors can harness the control of a patient's immune system and direct 
it towards tumor (Kruse et aI., 1 989; Merchant et aZ., 1 990). The RT-2 glioma model has 
been used extensively in our lab and others, is well characterized, and shares many 
features with human gliomas (Watts and Merchant, 1 992). The rat RT-2 glioma provides 
a model for immunotherapy for brain tumors. A major factor of significant importance is 
that the use of syngeneic RT-2 tumor cells in the syngeneic Fisher 344 rats is the 
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experimental results provide a provision of a consistent genetic basis for interpretation of 
results. 
A synopsis of these characteristics follows. Watts and Merchant (1 992) showed 
that glioma-bearing rats experienced ataxia with increasing tumor burden. These rats also 
lost approximately 25% of their body weight over the course of a two week study period. 
Immunological status showed a progressive decline as well as behavioral impairments 
and decreased functional activity. At seven days post tumor inoculation, they showed that 
animals displayed slight contralateral paralysis and delayed response to painful stimuli 
By Day 1 3  post RT-2 implantation, most rats exhibited diarrhea and a lack of grooming. 
Papilladema and periorbital hemorrhage due to increased intracranial pressure was also 
demonstrated. Without treatment, animals died between 1 4  and 1 7  days after Ie 
implantation of 1 0,000 RT -2 cells. 
Seven days after RT-2 glioma implantation, histological examination of brains 
revealed a small tumor with BBB permeability changes evidenced by extravasation of 
endogenous IgG in the adjacent cortex immediately around the tumor. Other changes that 
were demonstrated were: some of the vessels within the tumor displayed a little leakage 
of the protein tracer outside the vessel wall; less extravasation ofIgG was seen at early 
stages in tumor growth due to limited neovascularization of the tumor; there was no 
central necrosis due to small tumor size; and) and there was limited hemorrhage within 
the tumor. 
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As the glioma grew, they showed that there was no increased BBB permeability 
throughout the entire tumor and adjacent brain. The glioma was greatly increased in size 
at day 1 0  and 1 3  post-tumor implantation and compression of the underlying white matter 
had caused ventricular collapse. Also noted was the shift of the tumor-bearing 
hemisphere past midline as well as distortion of the contralateral hemisphere. Briefly, a 
summation of their findings regarding the presence oflgG in the tumor are that IgG 
extravasation was observed as an intense, dark brown immuno-reactive product within 
the surrounding cortex and white matter and that some of the larger vessels within the 
tumor exhibited permeability to circulating IgG. However, because of the densely 
organized tumor cells, the tracer was confined to the region immediately adjacent 
to the vessels. They also showed that limited extracellular space within the growing 
tumor prevented diffusion oflgG far into the tumor parenchyma; that the most intense 
staining was seen at the growing edge of tumor at Day 13 ;  and that as the tumor enlarged, 
more edema and hemorrhage was seen within the edematous peritumoral tissue. 
Primary Immunization 
Since no conventional treatment for glioma is deemed curative at this time, tumor 
biology, host reactions (immunogenic manipulations) and gene therapy have become a 
primary focus of investigators in the neuroscience field. Approaches to cancer using 
immunotherapy can be placed under the following three categories: ( 1 )  nonspecific 
immunotherapy consisting of methods designed to stimulate, augment or boost the 
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immune capacities o f  the cancer patient nonspecifically by various means, using 
adjuvants such as bacillus Calmett-Gurin (BCG), Corynebaclerium parvum, levamisole, 
and polynucleotides; (2) active or specific immunotherapy or vaccination, referring to the 
specific immunization of the patient with treated tumor cells, "tumor Ag" preparations, or 
cross-reacting viral or bacterial Ags in an attempt to specifically or selectively augment 
functional immune reactions; and (3) passive or adoptive immunotherapy involving the 
administration of immune cells, serum, or Ags from a specifically immunized host, in an 
effort to transfer specific immunity to the cancer patient. Since exposure to tumor Ags 
and cytokines in virro causes CD3+CD8+ populations of cytotoxic T lymphocytes to 
develop anti-tumor activity, we wanted to generate therapeutic cytotoxic effector cells in 
vivo against the RT-2 glioma cell line. The following experiments provide a glimpse of 
the usefulness and promise that manipulation of the immune system holds. 
Materials and Methods: 
Animals: 
Inbred female Fischer 344 rats weighing 120 to 1 40 grams and ranging in age from 4 to 6 
months were obtained from Harlan Sprague Dawley (Indianapolis, IN). Animals are 
housed in a climate controlled, AAALAC approved vivarium and were provided free 
access to rat chow and water. All experimental animal procedures have been approved by 
the VCUIMCV Institutional Animal Care and Use Committee. 
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RT-2 Cell Line and Cell Culture: 
The RT-2 glioma cell line was cultured in complete medium consisting of 
Dulbecco 's Modified Eagles Medium (DMEM ) (Ci11Jco BRL, Grand Island NY) 
supplemented with 1 0% Fetal Bovine Serum (FBS) ( Gibeo BRL) and non-essential 
amino acids. They were maintained as adherent mono layers in culture flasks, incubated at 
37° C in an atmosphere of 5% CO2 and 95% air and passed biweekly using 0.5% trypsin. 
RT-2 glioblastoma cell line is completely lethal when implanted IC into naive syngeneic 
rats. Irradiation of RT-2 cells was performed using the Cesium irradiator for I O  minutes. 
These cells were maintained on ice in 50 ml tubes. 
Mat-B ill Cell Line and Cell Culture: 
MAT-B III is a mammary adenocarcinoma cell line induced by 
dimethylbenzanthracene in a Fischer 344 rat (Segaloff; 1 966).The Mat-B III tumor cell 
line was cultured in complete medium consisting of DMEM (Gibco BRL, Grand Island 
NY) supplemented with 1 0% FBS (Gibco BRL) and non-essential amino acids. They 
were maintained as adherent mono layers in culture flasks, incubated at 37° C in an 
atmosphere of 5% CO2 and 95% air and passed biweekly using 0.5% trypsin. Mat-B ill 
cell line was completely lethal when implanted I C in RT -2 vaccinated rats. Intracranial 
Tumor Implantation: 
Tumor cells for IC implantation were trypsiniz.ed and washed twice with PBS and 
a final suspension of 1 xl 04 viable cells per 5 .ul of PBS was made. Animals were 
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anesthetized by an intraperitoneal (IP)injection of ketamineHCl (87 mglkg) and xylazine 
(6.5 mglkg). The scalp baIT was shaved, wiped with betadine and an incision was made 
over the cranial midline. Animals were placed in a stereotactic apparatus and bregma was 
located and used as a reference point for injections. A hand-held Dremel drill was used to 
create a shallow depression 4 mm to the right of bregma and 1 mm  posterior to the 
coronal suture. Five #1 of tumor cell suspension ( l x1 04 cells) was injected into the 
parietal 10be of the brain at a depth if 3.5mm using a Hamilton syringe and a 26-guage 
needle secured to the arm of the stereotactic apparatus. The needle tract was sealed with 
bone wax and the incision closed with surgical staples. 
Treatment #1: 
To determine if a 10 immunization with irradiated RT -2 glioma cells would 
sensitize rats to reject an IC challenge of viable RT-2 cells; and, to determine if the 
immunization would be tumor specific, a study was conducted to determine the survival 
times of rats after receiving a 1 0  immunization in the right (R) and left (L) HFPs with 
irradiated RT -2 tumor cells. There were 3 groups of animals with 1 0  animals in each 
group as seen in Table 1 .  At Day 1 ,  Group A (control group- I )  received sterile phosphate 
buffered saline (PBS) at 1 00 #1 per HFP. Group B (control group-2) and Group C 
(experimental group) received 4x1 06 irradiated RT-2 cells per HFPs. After one week., 
1 x1 04 viable RT-2 glioma cells were IC injected into the right cerebral hemispheres of 
Group A and Group C rats. Group B animals received 1x104 viable MAT-B III cells Ie. 
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The MAT-B III cells functioned as a control to show specificity of the vaccine to the RT-
2 cell line. All animals were monitored for survival. 
MA T-B III Cells Ie 
MAT-B III cells are from a mammary adenocarcinoma cell line induced by 
dimethyl-benzanthracene in a Fisher 344 rat (SegalofL 1 966). The Mat-B III cells 
functioned as a control to show specificity of the vaccine to the RT-2 cell line. (refer to 
Table 2 . 1 ). All animals were monitored for survival (see Figure 2. 1 ) .  
T b l  2 1  V a e . accmation an d IC Ch U a enge S h dul c e e 
Day 1 Group A (control group) n= 1 0  - received PBS ( l OOJ.lVHFP) 
Group B (control group) n= 1 0  - received irradiated RT-2 cells (4x1 0bIHFP) 
Group C n= l O  - received irradiated RT-2 cells (4x1 0olHFP) 
(experimental groups) 
Day ? Group A n=1 0  - Ie injection- 1 04 viable RT-2 glioma cells 
Group B n= 1 0  - Ie injection- 1 04 viable MAT-B III tumor 
cells 
Group C n=l O  - Ie injection - 1 04 viable RT-2 glioma cells 
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Results 
As seen in Figure 1 ,  the per cent survival in Control Groups A and B was 0%. A 
survjval rate of30% was attained in the experimental Group C and this extended beyond 
60 days. The PBS control group (A) showed a standard survival of l 6  days; the MAT-B 
ill group (B) showed an average range of survival of 1 8  days; and the RT -2 model (C) 
demonstrated 1 00% survival up to 28 days and 30% survival beyond 60 days. 
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Figure 2.1 Survival data from LC. RT-2 glioma implantation. 
Kaplan-Meier survival plot in which 3 groups of animals were implanted with I x l 04 RT-
2 glioma cells in the brain as previously described. All animals received a HFP 
vaccination of sterile PBS (0. 1 ml) or 4xl 06 irradiated RT -2 glioma cells. The results are 
representative plots of at least 3 independent studies. 
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Treatment #2: 
To determine if survival is influenced by the size of the inoculum. Experiment 2 
consisted of three groups with eight animals per group as seen in Table 2. Day 1 ,  Group 
A (control group) received 1 00 #1 of PBS IHFP. Group B (experimental group-I)  
received 4xl 06 irradiated RT-2 tumor cells in the NN. Group C (experimental group-2) 
received 4xl06 irradiated RT -2 tumor cellslHFP. At Day 7, IC injections of 1 04 RT-2 
cells were given in the right cerebral hemisphere were given to animals in all three 
groups. Day 1 - Group A (n= 8) received 1 00 #1 PBS. Group B (n= 8) received 4xl 06 
irradiated RT-2 tumor cells Group C (n= 8) received 8x1 06 irradiated RT-2 tumor cells 
Day 7- All 3 groups received IC injections of 104 RT-2 tumor cells in the R cerebral 
hemisphere. 
T hI 2 2  R a e . t th 1 °  epresen s e ti h duJ vaccma on sc e e an d Ie h II h d I c a enge sc e u e. 
Day Group No. of Animals PBS or RT-2 Cells Received 
1 A 8 received 1 00#1 PBS (HFP) 
B 8 received 4x1 00 irradiated 
RT-2 cells� 
C 8 received 8x1 00 irradiated 
RT -2 cells i!illl 
7 A 8 received IC injections of 1 04 
B viable RT-2 cells in the R 
C cerebral hemisphere 
Results: 
As seen in Figure 2, rats in Group A and Group B were all dead by day 1 7  post IC 
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challenge with viable RT-2 cells. Experimental C showed extended survival with 30% of 
these animals in the experimental group surviving beyond 60 days. In this case, the 
amount of the inoculum did make a difference in extending survival of rats receiving a 
total of 8xl 06 irradiated RT -2 tumor cells in the HFPs versus 4x1 06 irradiated RT-2 
tumor cells in the NN. The experiment should be repeated using these to sites for 
immunization but the amount of the inoculum should be the same. 
Discuss ion: 
The current forms of immunotherapy for human cancers can be broadly separated 
into two major categories, 1 )  cellular immunotherapy that is preventive and the subject of 
this dissertation, and 2) antibody-guided immunotoxin therapy. Any immune response 
eventually mounted against malignant gliomas in vivo in response to a 1 0  vaccination is 
clearly insufficient, as seen in Figure 1 ,  for eradication and prevention of tumor cells and 
tumor development. Data reported here, using the highly immunogenic RT-2 glioma as a 
primary vaccination followed by IC challenge, resulted in a 30% survival of challenged 
rats. Rats challenged with MAT-B ill showed a 1 00% death, which indicated that there 
was specificity of the vaccine. 
These data also raise questions regarding the fate of lymphocytes generated in the 
primary immune response. Primary responses ofT lymphocytes are initiated when Ag 
localizes in discrete micro-environments of the lymphoid tissues. These tissues are the 
peri-arteriolar lymphocyte sheaths of the spleen and paracortex of the LNs (Sprent, 
1 994). Naive recirculating lymphocytes not only perfuse these areas, but recognition of 
Ag at these sites causes a selective sequestration of Ag-reactive T cells. 
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According to Sprent ( 1 994), the MHC-bound antigenic peptides induce T cell 
trapping, such as displayed by interdigitating dendritic cells. Following trapping ofT 
cells, there is a rapid proliferation ofT cells that is assisted by the influence of cytokines. 
Cell expansion is a reflection of Ag concentration and affinity of the responding cells. 
The proliferating cells are capable of acquiring various effector functions and are then 
released into both vascular circulation and central lymphatic vessels after a period of 
several days (Sprent, 1 994). These primary immune responses, however can lead to either 
rapid clearance of Ag, or to an immune response of brief duration followed by a quick 
loss of the bulk of the effector cells generated in this response (Springer, 1 994). This 
suggests that in 70% of our rats, the primary immune response was an immune response 
of brief duration and disappearance of the bulk of effector cells. The 30% survival of rats 
in this experiment suggested that the actions of the APCs were such that the immune 
response resulted in the production of effector T cells and probably memory T cells. 
Direct evidence that proliferating T lymphocytes generated in a primary immune 
response may be rapidly eliminated has come from studies with super-Ags. Webb et aI., 
( 1 990), Kawabe and Oichi, ( 1991), and McDonald et aI., ( 1 991)  have shown that primary 
immune responses to super-Ags initially involve a strong Vf)-specific proliferation 
response in the spleen and LNs. This is followed by the entry of large numbers of blast 
cells into the blood and lymph. The progressive disappearance of responding T blasts is 
associated with a disappearance of the APCs (Webb et ai., 1 990). 
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The survival and proliferation of CTL during the effector phase of the immune 
response was probably critical for the elimination of tumor cells. Guiuntoli II et ai, 2002, 
reported that the expansion and cytolytic function of tumor-reactive human CTL can be 
enhanced by CD4+ helper T lymphocytes through co stimulatory signals that were 
mediated by cell surface molecules. Their work suggested that these co stimulatory 
receptors on CD8+ CTL were capable of interacting with corresponding ligands on T­
helper lymphocytes that resulted in enhanced proliferation and survival of the CTL 
during the effector phase of antitumor responses. These findings underline 1 )  the 
importance of Ag-specmc T - helper lymphocytes for regulation and maintenance of CTL 
immunity; and 2) have implications for the design of therapeutic vaccines for cancer. 
Chapter 3 
PRIMARY IMMUNIZATION FOLLOWED BY SECONDARY IMMUNIZATION 
Introduction 
A milestone in tumor immunology was the formulation of the cancer immuno-
surveillance theory by Burnett in the 1 960s. This theory postulated that cell-mediated 
immunity plays an important role in the control of cancer. The specific immune response 
can be divided into the humoral immune response - mediated by B lymphocytes and their 
Ag recognition product immunoglobulin and the cell-mediated immune response, which 
involves T lymphocytes. T lymphocytes as a whole are a diverse group of cells that can 
be broken down into the following subsets: Th cells, cytotoxic T (cT) cells and 
suppressor T cells CsT). Zimmerman et al., ( 1 996) subdivided T cells into naive, effector 
and memory subsets. Naive T cells are resting cells that have not encountered Ag after 
release from the thymus; whereas, effector T cells are activated cells. The presence of and 
recognition o f  Ag by effector T cells, enables them to perform specialized functions with 
high efficiency and without further differentiation. In Chapter 2, we found that a 30% 
survival was attained with a 10 vaccination only. Hence in this chapter, we investigated 
survival ofrats after receiving a 1 0 vaccination in the NN followed 14 days later by a 20 
vaccination o f  irradiated RT-2 glioma cells in HFPs. We theorized that the mechanism of 
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protection against the development of tumor in the animal glioma models, post 1 0  and 20 
vaccination with irradiated glioma cells, is an in vivo stimulation of effector and cytotoxic 
memory CD8+ T lymphocytes. 
Materials and Methods 
The materials for Chapter 3 are the same as described in Chapter 2. 
Treatment #3 
We wanted to determine if a 10 inoculation of irradiated RT-2 glioma cells in the 
NN , followed 1 4  days later by a 20 inoculation of irradiated RT-2 cells in the HFP would 
provide protection against development of glioma and prolong survival. The experiment 
had two groups of l O  animals per group as seen in Table 3 . 1 .  Group A (n= 1 0) was a 
control group that received a 1 0  vaccination of 1 00 III of PBS per NN. At Day 1 4, this 
group received a 20 vaccination of 1 00 III of PBS per HFP. An IC challenge Of l 04 RT-2 
viable glioma cells was done on day 2 1 . Group B (n=] 0) was an experimental group that 
received on day ] a 1 0  vaccination of 4 x l  06 irradiated R T -2 glioma cells in the NN. On 
day ]4,  this experimental group received a 20 challenge of 4x1 06 RT-2 cells per HFP. At 
day 2 1 ,  all 1 0  rats received an IC challenge of 1 04 viable RT-2 glioma cells. 
T b1 3 1  R C a e . epresents ontro1 Group A and Experimental Group B. 
Group Day of Treatment Animals Treatment 
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A 1 N=l O  control group 1 0  vaccination- received 1 00 ul of 
PBS in the NN; 
1 4  N=1 0  control group - 20 vaccination received 1 00ul 
PBS in the HFPs 
2 1  N=1 0  I e  challenge in R cerebral hemisphere with 1 04 
viable RT-2 cells 
B 1 N=1 0  experimental group; 1 0  vaccination - 4xl 0c 
irradiated RT-2 cells in the NN 
1 4  N=1 0  experimental group; 20 vaccination - 4 x I  06 
irradiated RT-2 cells per HFPs 
2 1  N=1 0  Ie challenge in R hemisphere - 1 04 viable RT-2 
cells 
Results 
As seen in Figure 3 . 1 ,  rats in Group A (n= l O) were all dead from tumor by day 
1 7. Rats in Group B (n= 1 0) attained 1 00% survival and showed no signs of tumor at the 
site one injection. These rats survived beyond 1 80 days. 
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Figure 3.1. A 1 °  and 2° Vaccination with Irradiated RT-2 Glioma Cells. 
Groups of animals received a 1 ° vaccination with either sterile PBS or 4x1 06 irradiated 
RT-2 glioma cells in the NN on Day 1 .  A 2° vaccination was administered on Day 7 of 
either PBS or 4xl 06 irradiated RT-2 cells per HFP. A Kaplein-Meier survival plot, which 
has combined the results of three independent studies, is shown. The survival of the RT-2 
vaccinated group shows significant survival and protection in comparison with the non­
vaccinated group. P< 0.000 1 .  
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Discussion 
Vaccination had an important role in reducing the mortality that is caused by RT-
2 tumor. The ultimate goal of the vaccine was to develop long-lived immunological 
protection, whereby the first encounter with RT -2 glioma is remembered, which leads to 
enhanced memory responses that either completely prevent re-infection or greatly reduce 
the severity of the disease. 
The memory T cell compartment consists of both CD4+ and CD8+ T cells that can 
acquire effector functions to kill infected cells and secrete inflammatory cytokines. 
Effector CD4+ T cells help in B-cell responses and enhance CD8+ T cell development, 
through the activation of APCs or secretion of cytokines such as IL-2, IL-4 and IL-5 .  
The context i n  which the T cell recognizes Ag, the abundance o f  Ag and the 
duration of Ag exposure are important parameters that can affect the speed and nature of 
the T-cell response (Kaech et al., 2002). The tenets ofT cell immunologic protection is 
well established in that the anamnestic response that is mediated by memory CD4+ and 
CD8+ T cells is more rapid and aggressive than the primary response. 
Kaech et aZ., (2002), reveal the physiological basis for the heightened recall 
responses of memory T cells: "( 1 )  as a consequence of clonal expansion during the 
primary infection, experiments in mice have shown that there can be a substantial 
increase ( 1 000 fold) in precursor frequency of Ag-specific T cells in immune animals 
54 
compared with naiVe animals; (2) as naIve T cells differentiate into memory T cells, their 
gene-expression profile is reprogrammed by changes in chromatin structure and the 
profile of active transcription factors. For example, the genes that encode IFN-y and 
cytotoxic molecules, such as perf orin and granzyme B, are not expressed in naive CD8+ T 
cells, but are constitutively expressed in effector and memory CD8+ T cells. Elevated 
levels of the messenger RNA transcripts endow memory CD8+ T cells with the capacity 
to produce larger quantities of these proteins more rapidly than naIve T cells. (3) Memory 
CDS+ cells express a different pattern of surface proteins that are involved in cell 
adhesion and chemotaxis from naive T cells, which allow memory T cells to extravasate 
into non-lymphoid tissues and mucosal sites. This enables memory T cells to survey 
peripheral tissues. Recently, memory CD8+ T cells that reside in these peripheral tissues 
have been termed 'effector' memory T cells, whereas those that are found in lymphoid 
organs are termed 'central' memory T cells; (4) memory T-cell populations are 
maintained for a long time due to homeostatic cell proliferation which occurs at a slow, 
yet steady pace. The rate of this homeostatic cell division must equal the rate of cell 
death, because the number of CD8+ T cells remains relatively constant over time." We 
can conclude from this, that when the secondary immune response in this experiment 
came into contact with the given Ag, it differed from the response produced after the first 
antigenic encounter as seen in Figure 2. The capacity to produce a secondary immune 
response or anamnestic response persisted long after the first encounter or contact with 
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the Ag. Thus it is the increased number o f  Ag-specific T cells, and their faster responses, 
anatomical location, and longevity that explain how memory T cells controlled long-term 
protective immunity in this vaccination treatment. 
Treatment # 4: 
We wanted to determine if a heightened immune response occurs at the site ofIC 
challenge in immunized rats that received a 2° vaccination. Contrast and comparison of 
the prophylactic immune response to an endogenous immune response was performed at 
days 3, 5 ,  and 7 post IC injection using three color flow cytometry and histology. Day 5 
showed significant changes in the presence of lymphocytes in the vaccinated versus the 
control animals as seen in the tables of F ACs analysis and histograms that follow. 
Methods: FACS Analvsis of Infiltrating Leukocytes 
RT-2 tumor tissue was excised and forced through a 70 pm nylon cell strainer 
(Fischer Scientific) using the butt of a sterile 3 cc syringe plunger. Cell suspensions were 
washed three times with cold 5% PBS-PBS. Viable leukocytes were enumerated using a 
hemacytometer and trypan blue exclusion and then were treated with a battery of 
fluorescently conjugated mAbs for F ACs analysis. l xl 06 cells were stained in V -bottom, 
96-well microplates (Costar Brand, Fischer Scientific) in a volume of 50 pI of 5% FBS­
PBS. Cells were suspended in a cocktail containing three monoclonal antibodies 
(mAbs)coupled to FITC, PE or biotin and incubated in the dark for 30 minutes on ice. 
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The mAbs were isotype controls, CD3E, CD4, CD8B, His 48 and CD45 
(pharmingen, San Diego, CA). After the primary Ab incubation, the cells were washed 
twice and incubated in streptavidin-PerCP (Bectin Dickenson Immunocytochemistry 
Systems, San Jose, CA) using a 1 :250 dilution for 30 minutes on ice. Finally, the cells 
were washed twice in a volume of SOp] of 5% PBS-PBS, fixed in 1 % paraformaldehyde 
and stored at 4° C until analysis was done. Three color flow cytometry analysis was 
performed using a Coulter Epics XL-MCL flow cytometer. 
Table 3.2: FACs Analysis of Cell Populations of Vaccinated Animals at Day 5 Post 
Ie Chall D 5 V . ted CD3/4/8 enge. ay aeema -
Region ID % 
C l  2.49 
C2 2 .84 
C3 93.1  
C4 1 .54 
Count 
21 
24 
787 
13 
Table 3.3: FACs Analysis of Cell Populations of Non-Vaccinated Animals at Day 5 
P t IC Ch II D 5 C tr 1 CD3/4/8 os a enge. l!Y on o -
Region ID % Count 
C l  1 .05 13  
C2 2.59 32 
C3 95 .9 1 1 85 
C4 0.49 6 
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Figure 3 .2  Normal F ACS stainmg for Tables 3.2 and 3.3 of T lymphocytes at Day 5 post 
IC challenge with viable RT-2 glioma cells. Lymphocytes were isolated from the brain 
for CD3€:, CD4 a� T lymphocytes and CD8 a� T lymphocytes in experimental animals 
(vaccinated) and control animals (non-vaccinated) animals. 
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Preparation and Staining of Brain Tissue From Day 1 and Day 5 Tumors 
Fixation of tissues was done by immersion with glutaraldebyde. In general, the 
tissue was fixed in 3% glutaraldebyde on a 0. 1 M sodium pbosphate buffer at 4° C and at 
a pH of 7.2-7.4 overnight. Tissue was then washed in 0.1  M sodium pbosphate buffer 
witb 2 changes, 5- 1 0  minutes each. Tissue was postfixed witb 2% osmium tetroxide in 
the 0 . 1  M buffer for 1 hour. This was followed by washing for 5 minutes with the 0 . 1  M 
sodium phosphate buffer. Debydration with a cold ethanol series followed. Vials were 
placed on a shaker to aid in dehydration. Ethanol series consisted of : 1 )  50% ethanol for 
5 minutes at 4° C; 2) 70% ethanol  for 5 minutes at 4° C, 3) 80% ethanol for 1 0  minutes at 
4° C; 4) 90% ethanol for 1 0  minutes at 4° C; 5) 1 00% ethanol for 1 5  minutes each. three 
cbanges at room temperature; and 6) propylene oxide for 20 minutes each, three changes, 
at room temperature. This step was followed by infiltration of the tissue with a half-and 
- half mixture of propylene oxide and Epon resin for 8 hours overnight. Samples were 
placed on a shaker to facilitate infiltration. The previous infiltrate was replaced with pure 
Epon resin and infiltration was done on a shaker for 8 bours. Embedding tissue in beem 
capsules and addition of resin followed. Beem capsules were placed in tbe oven at 60° C 
for 2-3 days. Thick section were cut and slides stained witb hematoxylin and eosin 
(H&E) or toluidine blue by Ms. Judy Williamson of the Department of Anatomy and 
Neurobiology. 
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Results: 
Based on our results in Treatment # 4, we decided to look at the histology of the 
area of brain parenchyma surrounding the needle track after Ie injection ofRT-2 tumor at 
days 1 and 5 .  We believe that 24 hours post Ie injection an immune response is mounted 
against the tumor cells. Day 1 and day 5 thick sections were stained with toluidine blue or 
H&E. One animal per time-point was harvested for histology. Day 1 histology 
demonstrated significant numbers of red blood cells (RBes) in the brain parenchyma at 
the site of the needle tract which was expected. At the same time, significant numbers of 
neutrophils were seen, not only in the brain tissue ,but within the vasculature. This acute 
inflammatory response at a site of injection would be expected due to the damage done to 
the brain parenchyma by the needle alone. 
Day 5 histology demonstrated the presence of monocytes in the blood vessels 
(Figure 3.3),  rolling along the luminal walls of blood vessels, tethering to the blood 
vessel wall and diapedesing through the endothelial cells into the brain parenchyma. 
Other cells of the immune system seen in this tissue were lymphocytes and mast cells. 
Mast cells were both granulated (Figure 3 .4) and degranulated (Figure 3.5) .Within the 
glioma cells of the tumor, many mitotic figures were seen in different stages of mitosis 
(Figure 3 .6). Necrotic area within the tumor bed is seen Figure 3 . 7 .  Macrophages in the 
brain parenchyma are also detected filled with phagocytosed hemosiderin (Figure 3 . 8).  
Figure 3.3 Histogram of Monocytes in Day 5 RT-2 Tumor 
The histology demonstrates the presence of monocytes in the lumen of a blood vessel. 
Tissue was stained with Toluidine Blue; magnification 20X. Rolling monocytes are 
indicated by a thick arrow; and tethered monocytes by a narrow arrow. 
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Figure 3.4 Histogram of G ranulated M ast Cells 
The histology demonstrates the presence of granulated mast cells located outside the 
lumen of a blood vessel Tissue was stained with toluidine blue and magnification was 
20X. Mast cells are indicated by arrows. 
63 
63 
65 
Figure 3.5 Degranulating Mast Cells in Neural Parencbyma 
The histology demonstrates the presence of degranulating mast cells located in brain 
parenchyma. Tissue was stained with H&E; magnification I OOX. Degranulated mast cells 
are marked by arrows. 
65 
67 
Figure 3.6 Mitotic Figures in Tumor Tissue 
Mitotic figures are numerous in tumor tissue. The arrow marks a mitotic figure present in 
this histogram. The tissue was stained with toluidine blue; magnification is l OOX. 
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Figure 3.7 Necrotic Tissue within Tumor Bed 
This histogram shows areas of necrosis within the tumor due to loss of angiogenesis. 
Tissue was stained with H&E; magnification l OX. The necrotic area is demarcated by 
asterisks. 
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Figure 3.8 Hemosiderin-filled Macrophages. This is a histogram of macrophages 
containing phagocytosed red blood cells and the by product - hemosiderin. Tissue was 
stained with H&E. Magnification is 1 00X Arrows are used to point out specific 
macrophages, but the hemosiderin-filled macrophages primarily fill the field. 
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Discussion: 
There bas been tremendous interest in the potential for immunotherapeutic 
manipulation of human brain tumors, and numerous studies have been performed to 
determine whether human brain tumors express Ags recognized by the immune system in 
the host of origin. As a result of those studies, a general consensus bas been reached that 
human brain tumors are not antigenic/immunogenic. The difficulty with human studies is 
that there are too many unknows: 1 )  it is not known whether human gliomas are 
antigenic; 2) whether the assays that were employed were appropriate for detection of 
antitumor responses; and 3) whether tumors progressing in the brain would induce 
detectable systemic immune responses even if the tumors were antigenic. The rationale 
for the current study was that some of those issues needed to be addressed under 
conditions where the number of unknowns was reduced. Thus, our studies were 
conducted to determine whether a relatively well defined experimental glioma that was 
1 00% lethal and known to induce detectable specific cytotoxic responses, would induce 
peripheral immune response when challenged in the brain. This work provided further 
support to the approach of developing methods of immunoprophylaxis of weakly 
immunogenic lines and human brain tumors. 
Chapter 4 
MEMORY LYMPHOCYTES FACILITATE SURVIVAL 
Introduction 
Immunological memory manifests itself as an accelerated and elevated response 
to a second stimulation by the same or closely related Ag (Mullbacher, 1 994). 
Establishment of long term memory underscores all protective vaccination strategies. 
One of the characteristics of an immune response is the acquisition of memory which 
focuses on establishment of long-term memory in the absence of constant antigenic 
challenge. We used rats that survived tumor challenge in Chapter 3 .  These data are well 
represented in our experimental model using a 1 0  and 20 vaccination in RT-2 glioma 
challenged rats that have survived beyond 1 80 days post first IC challenge and were then 
rechallenged in the left contralateral hemisphere. We hypothesize that these methods 
were able to generate long-term Ag-specific cytotoxic T lymphocytes. These T cells were 
long-lived lymphocytes involved in the experimental rats surviving beyond 60 days after 
IC challenge and this was attained without Ag repriming. These observations suggested 
that T cell memory is long-lived in the absence of RT-2 tumor Ag. 
M aterials and Methods 
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Animals and the RT-2 cells were prepared as mentioned in Chapter 2. 
Intracranial Tumor Implantation 
Tumor cells for IC implantation were trypsinized and washed twice with sterile 
PBS. Viable cells were identified by trypan blue exclusion, enumerated on a 
hemacytometer, and a final suspension of I xl 04 viable cells per 5 iiI of PBS was made. 
Animals were anesthetized by an intraperitoneal inj ection ofketamine'HCI (87 mg/kg) 
and xylazine (6.5 mglkg). The scalp hair was shaved, wiped with betadine and an incision 
was made over the cranial midline. Animals were placed in a stereotactic apparatus, 
bregma was located and used as a reference point for injections. A hand-held Dremel drill 
was used to create a shallow depression 4 mm to the left of the sagittal suture and 1 mm 
posterior to the coronal suture. Five iiI of the tumor cell suspension (I xl 04 cells) was 
injected into the parietal lobe of the brain at a depth on .5 mm using a Hamilton syringe 
and a 26-gauge needle secured to the arm of the stereotactic apparatus. The needle tract 
was sealed with bone wax and the incision closed with surgical staples. 
Methods of Determining Immunological Memory 
Treatment #5: 
To determine if immunological memory (long term memory) had been established 
in long term survivors. Group B animals from Table 4. 1 ,  that survived beyond 1 80 days 
after IC challenge of viable RT-2 glioma cells, were rechallenged in the contralateral left 
hemisphere with RT-2 tumor cells. Group A (control group) (n=1 0) were unvaccinated 
animals that received RT-2 tumor cells in the left cerebral hemisphere. 
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T bl 4 1  Lo T a e . ng enn Merom'" in Experimental Animals 
Group # of Animals Treatment Survival 
A n= 1 0  (control) IC challenge 0% 
1 04 RT·2 cells 
B n= 1 0 (experimental) I C rechallenge 1 00% 
1 04 RT -2 cells 
Results: 
The control Group A, showed 0% survival. All of Group A ( control rats) died by 
Day 2 1  post implantation. The control rats had received sterile PBS as a vehicle instead 
of RT-2 glioma cells. Results o f rechallenge in the left hemisphere showed 1 00% survival 
for Group B experimental animals from Table 3 . 1 .  These animals survived beyond 60 
days. 
Discussion: 
Peripheral T lymphocytes can be classified into two groups: naive and memory T 
cells. The focus of this study was to examine the duration ofT cell memory in long-lived 
rats. The ability of a T cell to recognize a specific peptide epitope in the context o f MHC 
molecules by APCs from tumor cells is provided by its T cell receptor. The interaction 
between T cell receptor and the Ag-MHC triggers proliferation and clonal expansion of 
specific T cells. Some of the progeny of the Ag-responsive T cells develop into Ag-
specific memory T cells. This subpopuIation of T cells is maintained within the host and 
provides immune surveillance. In the event of reactivation by subsequent re-exposure to 
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the tumor, specific memory T cells become activated and c10nally expand with greater 
magnitude than during the initial response. It is generally accepted that specific immune 
T cell memory persists after an encounter with an Ag and may help to protect the immune 
host against subsequent exposure to that pathogen. 
The experiments performed in this chapter suggested that specific immunity was 
induced by 1 0  and 20 vaccinations with viable irradiated RT -2 glioma cells in HFPs and 
the NN . The first IC challenge was in the right cerebral hemisphere. The experimental 
rats that survived were rechallenged 1 80 days beyond the first challenge in the left 
cerebral hemisphere. Control rats died between days 1 6  and 1 8  after I C challenge with 
tumor cells. 1 00% survival was seen in the left cerebral hemisphere challenged rats. We 
have reported on a series of experiments that suggested that immunological memory in 
rats that received multiple vaccinations with the immunogenic RT -2 glioma cell line 
could be developed and persist. In the first experiments, rats vaccinated by subcutaneous 
injections of RT-2 cells were challenged in the right cerebral hemisphere. The 
immunological response was specific and these animals remained protected after a 
rechallenge with RT -2 tumor cells in the left cerebral hemisphere. This work provides 
further support to the approach of developing methods of imrounoprophylaxis to treat 
weakly immunogenic lines and human brain tumors. 
Chapter 5: 
MEMORY LYMPHOCYTES PROTECT AGAINST THE DEVELOPMENT OF 
RT-2 GBMS 
Introduction 
Active, specific immunotherapy with anti-cancer vaccines offers the possibility of 
stimulating the intrinsic immune response of a patient to his or her tumor, with the 
development of long-term immunologic memory through helper and cytotoxic T cells. 
This vaccine may assist prophalactically in the protection of tumor development and 
rejection of existing tumor cells. It may also help in surveillance against their re-
emergence. A draw back to some experimental studies may be seen in the fact that 
vaccination-based immune therapy for cancer must be shown to work in the presence of a 
pre-existing neoplasm In contrast to this type of immune treatment, we want to address 
the use of classical vaccination strategies which are preventive. 
These experiments examined the use of various leukocytic suspensions, from the 
spleens of 1 0  and 2° vaccinated rats that had survived for more than 2 1 0  days, as 
vaccines. Seven days prior to harvesting the spleens, animals received a booster of 1 04 
irradiated RT-2 glioma cells in the right hind flank. 
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Materials and Methods 
Animals and the RT-2 cell line were treated as mentioned in Chapter 2. 
Treatment #6: 
To deplete various lymphocytic cell populations from spleen cells ofrats that 
received a 1 0  and 20 vaccination at least 2 1  0 days prior to harvesting spleens. Splenocytes 
were selected for transfer because of convenience versus use of lymph nodes. Table 5 . 1  
gives a breakdown o f  leukocytic makeup by % as determined by Dr. Martin Oraf. 
Table 5.1 Percent makeup of leukocytic cells in spleen 
Leukocytic Cells Percentage 
B Lymphocytes 35% 
CD4+ T Lymphocytes 25% 
CD8+ T Lymphocytes 1 0% 
Natural Killer Cells 1 0% 
Monocytes 1 0% 
Others 5% 
The purpose was to examine and determine which effector and long-term memory 
cells were necessary for transfer to provide protection to naive rats before IC challenge 
with viable RT-2 glioma cells. The spleen-donor rats (n=6) received a booster of 1 04 
irradiated RT-2 glioma cells delivered in sterile PBS in the right hind flank to up-regulate 
the secondary immune response. 
Seven days post hind flank injection, spleens (n=6) were harvested from the 
vaccinated rats. To obtain cells, spleens were aseptically minced and pushed through a 
8 1  
nylon mesh by use o f  the butt of a plunger from a sterile 3 ml syringe. The leukocytic 
population was pooled and consisted of the following groups as seen in Table 5 .2. Group 
1: T and B cells together as a passive transfer of a whole cell suspension; Group 2: CD4+ 
T cell-depleted suspension; Group 3 :  CD8+ T cell-depleted suspension; Group 4: pan T 
cell-depleted suspension; and Group 5 :  sterile PBS (control group). Pmity of cells 
transferred was 90%. The number of cells transferred was 4xl 08 per group. For future 
studies, we will alter the numbers of the various lymphocytes (increase or decrease) 
transferred accordingly. 
Twenty four hours after receiving an IP injection of a particular cell suspension or 
PBS, experimental and control rats received IC injections of viable RT-2 cells ( l x l 04) in 
the right cerebral hemisphere. The animals were observed for survival. 
Results: 
Group 1 = whole cell suspension = 2/3 rats survived. Group 2 = CD4+ T cell-depleted 
suspension = 3/3 rats succumbed to tumor. Group 3 = CD8+ T cell-depleted suspension = 
2/3 rats survived. Group 4 = pan T cell-depleted cell suspension = 1 /3 rats 
survived. Group 5 = sterile PBS control = 3/3 rats succumbed to tumor. See Table 5 .2. 
T bl 5 2 D I · St d· a e epletlOn U les an 
Groups Cell Suspension 
1 whole cell sus�ension 
2 CD4+ T cell-depleted 
3 CD8+ T cell-depleted 
4 pan T cell depleted 
5 sterile PBS 
d S . I UrvIVa 
N-3 
3 
3 
3 
3 
.., .J 
Animal Survival 
2 
0 
2 
1 
0 
Deaths Days Survived 
1 30 Days 
3 20 Days 
1 30 Days 
2 30 Days 
., 1 7  Days .J 
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Discussion: 
A central observation in immunology is the finding that upon a secondary contact 
with a given Ag, the immune response obtained differs from the response produced after 
the first antigenic encounter. The secondary response that produces effector/memory T 
lymphocytes persists long after the first encounter with Ag. This memory property of the 
immune system, together with two other characteristics, specificity and diversity, makes 
the immune system an attractive biological entity to investigate prophylactic treatment by 
use of vaccines to prevent development of or treatment of brain tumors. The morbidity 
and mortality caused by infectious diseases has been reduced by the important role of 
vaccination. The ultimate goal of vaccines is to develop long-lived immunological 
protection, whereby the first encounter with a pathogen is remembered. This leads to 
enhanced memory responses that either completely prevent re-infection or greatly reduce 
the severity of the disease. It has been well established that the anamnestic response that 
is mediated by memory CD4+ and CD8+ T cells is more rapid and aggressive than the 
primary immune response (Kaech, et al., 2002). This faster T-cell response can control 
secondary infections quickly and fully eliminate the pathogen. In our previous 
experiments based on mT cells, the emphasis was placed on CD8+ cytotoxic lymphocytes 
for long-term survival 
However, in this last experiment that involved depletion studies of CD4+ T cells 
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and CD8+ T cells in cell suspensions created from harvested spleens of long-term 
survivors to RT-2 glioma challenge, CD8-depleted cell suspensions given to rats 
followed by IC injection of viable RT-2 tumors demonstrated long term survival. The 
suspension that was CD4-depleted was not able to protect against the development of 
RT-2 tumor and ultimate death. These rats did survive longer than naive rats that received 
IC challenge only, but they finally succumbed to tumor. The results of this experiment 
suggested that the presence of transferred memory CD4+ T cells played a significant 
immunological role required to provide protection against IC tumor challenge with viable 
RT-2 glioma cells. This is in contrast to the lack of survival seen in animals that received 
CD8+ T cells and no CD4+ T cells in the cell suspension. 
The results of this experiment suggested that the presence of memory CD4+ T 
lymphocytes were required for protection against a challenge of viable RT-2 glioma cells. 
The protective mechanism could possible have been that CD4+ T cells were capable of 
production of the cytokines IL-2 and IL-4. 
The production of these cytokines created a division of CD4+ T cells into two 
separate entities. T lymphocytes are divided into Th- I cells that are responsible for 
production of IL-2, INF-y, and IL-12.  Th-2 cells are responsible for the secretion of IL-4, 
IL-3, IL-5 and IL-6.These cytokines play a pivotal role in the communication network of 
cells. Pleiotropic functions associated with the IL-4 cytokine was first described to 
enhance DNA synthesis of purified resting mouse B cells (Topp et al. , 1 995). Topp et al., 
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1 995, suggested that the following cell lines were involved in the production ofIL-4: 
CD4+ T lymphocytes and to a lesser extent by mast cells and human tumor-associated 
natural killer celIs. CD4+ T cells are pivotal in the immune response in that they control 
the development and activation ofB lymphocytes, CD8+ T cells, macro phages, and other 
inflammatory celIs (Bunce and Be1l, 1 997). 
Functional properties of IL-4 include ( 1 )  activation of resting B celIs, (2) 
enhancement o f IgE production in activated B lymphocytes, (3) an increase in expression 
of the low-affInity receptor for 19E, (4) a co-stimulant for resting T celIs, and (5) their 
activation of cytolytic CD8+ T lymphocytes. 
A number of studies have examined the ability of naive and memory CD4+ T cells 
to synthesize cytokines after activation. Similar observation on CD8+ T cells have been 
performed but observations suggest that naive and memory CD8+ populations can 
synthesize cytokines, but to a lesser extent than the CD4+ population (Akbar, 1 99 1 ) .  
According t o  Akbar, 1 99 1 ,  IFN-y, IL-3 and IL-6 are preferentially synthesized by the 
CD4+ memory T cell population rather than by the naive celIs. 
These results strongly indicate that CD4+ T cells were required for long term 
survival. These cells were a mixed bag. Therefore, three possibilities existed: 1 )  a 
humoral response promoted by CD4+ T cells; 2) CTL response promoted by CD4+ T 
cells; and 3) presence of cytotoxic CD4+ T cells. Our primary focus was number two. 
The data presented here can be interpreted in a number of ways, but a hypothesis 
85 
which incorporates our findings is the lack of induction of effective antitumor reactivity 
against parental RT-2 cells in a CD4-depleted cell suspension. This could be due to a 
paucity of memory helper cell function, as welJ as a consequence of suppressor factors 
expressed by tumors. The ability of these rodents to survive beyond 20 days, possibly 
represents an attempt by mCD8 + cytotoxicT cells to perform in a cytotoxic role. 
However, without CD4+ effector/memory T cell help, the numbers of mCD8+ cytotoxic T 
cells probably declined along with production ofIL-2. This reduction in IL-2 could 
inhibit the activation of naIve T cells to become a large CD4 and CD8 effector 
population. This, along with tumor suppressor factors, had a potential significant effect 
allowing tumor to escape the cytolytic activities of CD8+ lymphocytes. 
The mechanism(s) by which CD4+ T cells contribute to the initiation and 
persistence of CD8+ T cell responses remain incompletely defined. Until recently, CD4-
dependent help for CTL responses was thought to result primarily from the production of 
IL-2 to support activation of CD8+ T cells (Wagner et al., 1 980; Keene, 1. and Forman J., 
1 982). An additional mechanism for the provision of help in which CD4+ T cells interact 
with APC in a CD40-dependent manner to "condition" the APC for effective activation 
of CD8+ T cells has been recently demonstrated ( Ridge, 1. et al., 1 998; Bennett, S. et al., 
1 998; and Schoenberger, S. et al., 1998). 
In some cases, CD4 help is necessary to initiate CTL responses. However, CD8+ 
T cells can produce their own IL-2 response to co stimulation to drive activation in the 
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absence of CD4+ T cells (Azumi, M. et ai., 1 992; Harding, F. and Allison, J., 1 993; and 
Deeths, M. and Mescher, M., 1 997). A CTL response occurred in the absence of help but 
the response only persisted if CD4-dependent help was available. This was true in a 
number of models of virus infection, tumors, and autoimmunity (Tham, E. et ai., 2002). 
This suggested that different mechanisms might operate at differing stages of CD8+ T cell 
activation, differentiation, clonal expansion, and survival. 
Tha.m. E., et at., (2002) demonstrated that if IL-2 was absent 3 days after the 
activation response in CD8+ lymphocytes was initiated, the cells lost the ability to make 
further IL-2 in response to Ag and co stimulatory ligands, and clonal expansion ceased. 
They described this non-responsiveness as resembling the "anergic" state originally 
described for CD4+ T cell clones following TCR engagement in the absence of 
co stimulation. In the CD8+ CTL population, it was distinct, in that it occurred following 
full stimulation through both the TCR and co stimulatory receptors. Tham, E. et at. , 
(2002) have termed this state of CD8+ T cells "activation-induced nomesponsiveness" 
(AJNR) to distinguish it from the classical anergy that occurs when T cells receive just 
one signal. Further examination resulted in the demonstration that the AINR state was 
reversed if continued proliferation was supported for a short time ( 1 -2 days) by provision 
of help in the form of IL-2. After this, the CD8+ T cells regained the ability to produce 
IL-2 and continued to respond to Ag in an autocrine-driven manner for prolonged times 
(Tham, E.,  et a/., 2002). 
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In conclusion" helper-independent initiation of CTL responses have been 
demonstrated in numerous models examining virus infection" tumors, and autoimmunity 
but these responses have often failed to persist in the absence of CD4+ T cell help. NaIve 
T cells responded to Ag and co stimulation by producing IL-2 to drive their initial clonal 
expansion" but within a few days the cells became AINR. They could still be signaled 
through the TCR to carry out effector functions but could no longer produce IL-2 to 
sustain expansion. However, the CTL could continue to proliferate ifprovided with IL-2. 
This suggested that the basis for the requirement for CD4+ T helper cells is to sustain 
effective CTL responses in many instances. 
Chapter 6 
GENERAL DISCUSSION AND LITERATURE REVIEW 
The successful application of immunological methods to the diagnosis and control 
of clinical infectious disease during the 1 9th century had a resounding influence on the 
reach of medical aspirations (Hewitt, H., 1 982). It fostered a hope that soon hardened into 
conviction that human malignant disease would eventually yield to similar approaches. In 
the 1 800s, physicians noticed that tumors sometimes regressed in cancer patients who 
contracted bacterial infections. Therefore, the clinical support for the idea that the 
immune system might restrain the development of cancer emerged. William B. Coley, a 
surgeon at Memorial Hospital in New York City from 1 892 to 1 936, dedicated his life to 
creating therapies based on this observation (Old, L., 1 998) These treatments are now 
considered immunotherapies because they aimed to attack disease with the body's own 
defenses that brought about complete tumor regressions in some individuals. Deliberate 
attempts were made by him to infect cancer patients with bacteria He later developed a 
vaccine consisting of killed bacteria to prompt a tumor-killing response. However, 
because the results were unpredictable, they were not widely accepted. 
During the 20th century, the search for oncogenic agents and exploration of 
immunological aspects of clinical cancer have persisted. In the early decades of the 20th 
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century, experimental cancer research was confined to the use of allo-grafted animal 
tumors. The high frequency of induced or spontaneous regression sustained the concept 
ofturnor immunity. By the 1 920's it had been disclosed that autochthonous animal 
tumors displayed no such phenomena, and the subject of clinical tumor immunity was 
considered closed ( Leitch, A., 1 920). In 1 943 it was reopened; Gross had demonstrated 
that xenografts ofa chemically induced tumor were immunogenic (Gross, L., 1 943). 
However, the repeated demonstration during the 1 950's, that animal tumors were of 
spontaneous origin, invariably failed to display the immunogenicity shown by nearly all 
chemically induced tumors was ignored (Foley, E., 1 953;  Prehn, R., 1 957; and Revesz, L. 
1 960). 
In 1 965, ROllS (Rous, P., 1 965), a pioneer of viral oncogenesis, used the occasion 
of his Nobel address to warn against generalization of a concept of viral oncogenesis 
beyond the meager evidence supporting it. Cancer-causing viruses were not, he said, an 
"Open Sesame!" to the cancer problem (Hewitt, H. , 1 982). Proponents of a topic that was 
confidently flourishing previously came to write discouraging titles as ''Back to the 
drawing board . . .  " ( Alexander, P., 1 977), "The questionable immunogenicity of certain 
neoplasms" (Weiss, D., 1 977) " . . .  non-rejectability of spontaneous tumors . . .  ( Klein, G., 
and Klein, E. ,  1 977); and "The case history of Mr. T.!. - Terminal patient or still 
curable?" (No ssal, G., 1 980). Still , the link between immunity and cancer remained 
frrmly fixed in the minds of many people. During the 1 960s and 1 970s there was wide 
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acceptance of the "immunosurveillance" model put forth by Lewis Thomas of New York 
University and MacFarlane Burnett of the Hall Institute in Melbourne, Australia (Old, L.,  
1 998). This theory held that the immune system constantly seeks out and destroys 
emerging cancer cells. Tumors, it proposed, arise when this policing mechanism failed. 
Because accumulating evidence suggested that the immune system attacked only tumors 
caused by viral infections and this accounted for only a small number of tumors, the 
theory appeared flawed. 
Coley' s  approach to cancer therapy was described as nonspecific: it strengthened 
the overall activity of the immune system instead of selectively arousing those elements 
most able to combat cancers. During the last century, scientists developed a range of 
other nonspecific immunotherapies - e.g. Bacillus CaImette-Gurin, or BCG as a vaccine 
to treat bladder cancer (Old, L., 1 998). Although this vaccine illustrated the potential of 
non-specific immunotherapies, it acted locally, provoking inflammation only in the 
bladder. Most cancers become lethal because they spread and give rise to tumors at a 
distance. To eliminate these growths, immunotherapies had to be capable of seeking out 
incipient tumors in all parts of the body. To accomplish this, many research oncologists 
turned in the 1 970' s  and 1 980's  to molecules the body produced in response to viral and 
bacterial infections, now called cytokines, to help orchestrate the defense response. The 
cytokines included such proteins as interferons, interleukins, and tumor necrosis factor. 
Extensive clinical testing of this nonspecific approacb dampened enthusiasm because 
relatively few patients appeared to benefit from cytokine therapy alone (Old, L.,  
1 998). Cytokines have proven more valuable in combination with one another or with 
other treatments. 
The discovery of antibodies at the end of the 1 9th century provided the means to 
search for such cancer-specific Ags and later opened the way for extensive studies of 
antibodies as potential immunotherapies for cancer (Old, L., 1 998). Antibodies are a 
critical component of the immune system and circulate in the blood and bind to foreign 
Ags. Therefore, they are able to mark Ag-bound invaders for destruction by scavenger 
cells called macrophages, by other cells and by special blood protein components, 
collectively called complements. 
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I n  1 975, the search for Ags became easier. This was made possible by the 
discovery made by Cesar Milstein and Georges J. F. Kohler of the University of 
Cambridge (Old, L., 1 998). These researchers demonstrated that Ab-producing cells 
could be made to survive indefinitely if they were fused with cancer cells. This technique 
enabled scientists to produce unlimited supplies of identical Abs, because any given Ab­
producing cell produces only a single species of Ab. This method profoundly effected 
cancer immunology for several reasons. First, it provided a powerful new method to 
search for cancer antigens. Secondly, defined Abs could be produced in sufficient 
amounts to put Ab-based therapies to the test (Old, L. ,  1 998). 
Monoclonal antibodies have revealed a large array of Ags that exist on human 
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cancer cells. However, virtually all these Ags are also found on normal cells. These 
normal cells might be damaged by an Ab-based therapy. This overlap does not preclude 
their use as therapeutic targets for several reasons: the Ag in normal tissues may not be 
accessible to blood-borne antibodies; the cancer cells may express more Ag than normal 
cells do; and antibody-induced injury of normal cells may be reversible. In the Ab-based 
vaccines discussed, the injected Ab is derived from an animal. The treatment is 
considered passive immunotherapy: the immune molecules are given to patients, who do 
not produce them on their OWD. A vaccine, however, is deemed active immunotherapy 
because it rouses an immune response in the individual who needs protection. The 
technology of Ab production gave rise to high expectations as well as to premature and 
unrealistic assertions about Abs as "magic bullets" (Old, L., 1 998).By recognizing 
specific Ags, it was hoped that monoclonal Abs would home in on cancer cells and 
trigger an immune attack that destroyed the target cell but ignored normal cells lacking 
the cancer Ags. Many expected that these bullets would be more deadly by loading them 
with toxic chemicals; the Abs would carry the toxins directly to the tumor, where the 
poisons would kill cancer cells. At first the technology was declared a :failure. The reality 
of the situation was fur more positive. The concept remained sound, and slow, steady 
progress has been made in developing Ab therapies. Today, Abs can target cancer cells 
and act on other cell types and molecules necessary for tumor growth. Antibodies can 
neutralize growth-factors chemicals needed by tumor cells and their blood supply and 
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thereby inhibit a tumor' s  expansion. Antibodies can also target the stroma, the connective 
tissue between tumor cells (Old, L., 1 998). This and other Ags that mark tumor stroma or 
blood vessels have become attractive targets to researchers devising Ab-based therapies. 
As previously mentioned, tumors of the CNS are poorly responsive to the three 
modalities of conventional anticancer therapy: surgery, radiation, and chemotherapy. 
However, since the demonstration of immunogenicity of chemically induced tumors in 
mice, it has been the goal of tumor immunologists to develop novel approaches to cancer 
therapy based on manipUlating antitumor immunity (prabir, K.. et aZ., 1 992). Some of the 
strategies presented by these authors include (a) active specific immunotherapy with 
autologous or allogeneic irradiated tumor cells or their extracts in the presence of 
adjuvants,(b) infusion of large doses of interleukin-2 (IL-2) with or without lymphokine­
activated killer (LAK) cells, and (c) adoptive immunotherapy involving in vitro 
activation and amplification of tumor-infiltrating lymphocytes followed by their infusion 
into a tumor-bearing host. Clinical trials employing these approaches have been 
conducted. The use of immunotherapy as a clinical tool has been an area of enthusiasm 
and intense investigations. 
Adoptive immunotherapy, whereby immunoreactive cells with antitumor activity 
were transferred into the tumor bed at the time of debulking, was an approach for 
potential treatment of high-grade gliomas. With the advent of recombinant DNA 
techniques, recombinant IL-2 (rIL-2) was available in sufficient quantity to allow the 
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generation of greatly expanded numbers of activated lymphoid cells for therapy (Kruse et 
al., 1 989). 
Lillehei, K. et al., 1 987 began clinical trials that involved intratumoral 
implantation of both preparations of lymphocytes, together with rIL-2, in patients with 
recurrent, high grade gliomas. The lymphokine activated killer (LAK) cells and 
autologous-stimulated lymphocytes (ASL) were successfully generated from the PBL of 
brain tumor patients. 
Kruse et al., 1 989 described two separately activated preparations of cells, 
derived from peripheral blood to use therapeutically against brain glioma. One 
preparation was widely known as lymphocyte activated killer cells. The other preparation 
was termed autologous-stimulated lymphocytes. These are lectin-responsive and 
combinant IL-2-responsive cells. Clinical researchers have reported the use of LAK cells 
against brain tumors (Jacobs, S. et al., 1 986 and Merchant et aI., 1 988). Others have 
reported the similar use of ASL (Ingram, M. et al., 1 987; and Ingram et aI., 1 987). Two 
separate studies examined the capacity o f PBL obtained from glioma patients to respond 
to PHA and rIL-2 stimulation. Yoshida et al., 1 987, concluded that PBL from patients 
with malignant brain tumors produced a level of IL-2 lower than that of normal control 
subjects because of the decreased number of IL-2 producing T cells. PHA-activated PBL 
from both responded equally well to rIL-2. Elliot et al., 1 987, also found that rIL-2 did 
not improve the PHA responsiveness of PBL from patients who had not received 
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radiation, steroids, or phenytoin. Kruse et ai. ' s, 1 989 data showed that there was a 
statistically significant difference in the short-term cytotoxicity against all targets of brain 
tumor patients' PBL stimulated with rIL-2 alone (LAK.) versus those stimulated with 
PHA and rIL-2 (ASL) . They have found that in long-term cytotoxicity assays this 
difference disappears. Kruse et aI., 1 989, suggested that different types of activated cells 
were responsible for the target cell lysis, and that they perhaps killed in a mechanistically 
different fashion. The difference may have been due to the fact that LAK. cells did not 
recycle as well as other activated T-cells and/or NK cells. Their work also suggested that 
the effector cells could produce stasis of glioma by producing lymphokines such as tumor 
necrosis factor, leukoregulin, interferon, and lymphotoxin (Merchant, R et aI., 1 986). 
The results of this study by Kruse et aI., 1 989, showed that the production of ASL 
was labor intensive, involving long-term culture and a greater chance of contamination. 
Kruse et ai., 1 989, studied the LAK. cells and ASL preparations and compared them to 
the starting PBL by growth and viability measurements, cytotoxicity, phenotype 
expression using specific monoclonal antibodies to characterize cell surface proteins, and 
morphology as seen by electron microscopy. They determined that the two preparations 
were distinct and that both were tumoricidal against known tumor cell lines. However, 
LAK. cells and ASL derived from the peripheral blood of patients with intrinsic brain 
tumors exhibited a wide variation in their capacity for in vitro growth. This could be 
explained, in part, to the chemotherapy that patients received (Kruse et ai., 1 989) . The 
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modern vaccine story starts in the 1 940s and 1950s with a fundamental discovery of 
tumor immunology. Scientists found that when chemicals or viruses induced tumor in 
mice, the tumor bore Ags that could immunize other mice of the same strain against 
transplants of the tumor. Subsequent studies showed that immune system cells known as 
T lymphocytes taken from immunized animals could transfer immunity against tumors in 
healthy animals of the same strain. Workers also devised techniques to show that the T 
cells from immunized mice could kill tumor cells grown in test tubes as well (Old, L., 
1 998). Antibodies elicited by the tumor cells generally failed to transfer immunity or kill 
tumor cells. 
The next challenge was to isolate the tumor Ags recognized in this system so that 
they might be tested in a vaccine. Thierry Boon, 1993, and his colleagues at the Ludwig 
Institute for Cancer Research in Brussels developed a method to do just that (Old, L., 
1 998). The technique revealed two main categories of tumor Ags that evoked a T cell 
response in melanoma patients. According to Old, L., 1 998, the first category of Ags 
called MAGE, BAGE, and GAGE that were produced by tumor cells but not by normal 
cells outside the testes. The second category of Ags, including tyrosinase and Melan A, 
were called differentiation Ags; they were made from by both melanoma cells and 
melanocytes, normal cells from which the tumor cell arises. 
Another source of information about potential tumor Ags comes from the 
discoveries concerning genetic changes in cancer cells. Among the most attractive targets 
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for vaccines are abnormal proteins that are made when genetic mutations turn normal 
genes into cancer-promoting versions. A long list of cancer-related genes - known as 
oncogenes and tumor suppressor genes - are being compiled. Although much uncharted 
areas lie ahead, there are now more vaccine-based therapies than before and promise 
hope for the future. 
The studies that comprised the formal research basis for this dissertation included 
the following projects: 1 )  examination of the ability ofa 1 °  vaccination to protect against 
RT-2 tumor and the demonstration of that specificity; 2) examination of the ability of a 
1 0  and 20 vaccination paradigm to provide protection against an I C challenge of viable 
RT-2 glioma cells; 3) examination of memory T cells in vaccinated and aged rats and 4) 
examination of depletion studies to see if passive transfer of effector/memory cells was 
possible. 
To address the questions put forth, a highly immunogenic glioma cell line (RT-2) 
was used. The RT-2 glioma cell line is uniformly lethal, whether implanted s.c. or IC. It 
provides an efficient animal model in which to explore the efficacy of lymphokine and 
cellular immunotherapy for brain tumors. The RT-2 glioma model has been used 
extensively in our lab and others, is well characterized, and shares many features with 
human gliomas. 
We have described an experimental system in which vaccination with irradiated 
RT-2 glioma cells activated an immunological response against the tumor. This was 
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achieved in the 1 0  vaccination paradigm with 30% survival and in the 1 0  and 20 
vaccination paradigm with 1 00% survival seen in animals with IC challenge in the right 
cerebral hemisphere with viable RT-2 tumor cells. These data have described an 
experimental system in which a population of resting, primed CD4+ T lymphocytes and 
CD8+ CTLs can be generated in vivo and migrate to and initiate an immune response to 
the tumor cells. 
Immunological memory is described as the capacity of the immune system to 
respond faster and more efficiently against an Ag it has encountered in the past. T cell 
memory is believed to result from an increase in the frequency of Ag-specific T 
lymphocytes (Ahmed, R. and Gray, D., 1 996; and McHeyzer-Williams, M. and Davis, 
M., 1 995). Our results suggested that these populations of cells contributed to the 1 00% 
survival rate. 
Specialized cells known as memory T cell and B cells, and long-lived effector B 
cells (plasma cells), which constitutively secrete high-affinity 'neutralizing' antibodies, 
are the basis of immunologic memory (Kaech, S.,  et aL, 2002). The memory T cell 
compartment consists of both CD4+ and CD8+ T cells that acquire effector functions to 
kill infected cells andlor secrete inflammatory cytokines that inhibit the replication of 
pathogen. Effector CD4+ T cells also help B-cell responses and enhance CD8+ T cell 
development, through the activation of APCs or secretion of cytokines, such as IL-2, IL-4 
and IL- 1 5 .  Although there might be interesting parallels between T - and B-cell 
development, this work focused primarily on the formation of effector and memory T 
cells. 
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In the first study, we found that a 1 °  vaccination of irradiated RT-2 cells in the 
HFPs or NN saw 30% survival of experimental animals. This was promising data that 
directed the next set of experiments. Again, in the second study a vaccination paradigm 
followed the first experiment. This one required a 1 ° and 2° vaccination of irradiated cells 
in the NN and HFPs. Complete survival was attained in the experimental animals and all 
control animals succumbed to tumor. 
In the third set of experiments, we treated long-lived immunized rats with a 
secondary IC challenge in the opposite hemisphere 1 80 days post first IC challenge. This 
group of animals also resulted in 1 00% survival in the experimental rats and no survivors 
for the control group. 
The fourth experiment was performed to answer the questions if we could 
passively transfer memory lymphocytes from spleen leukocytes from long-lived 
immunized and challenged rats. This was done in the form of depletion studies. The 
results were interesting in that the CD8+ T cell depleted group survived longer than the 
CD4+ T cell depleted group. Future studies should look at the naIve and memory 
populations using the CD45 mAbs markers that are available for humans, mice and rats. 
Then one could look at the relative numbers of naIve T cells versus memory T cells 
during a vaccination or vaccinations. The cytokines 1L-2 and 1L-4 involvement in CD4+ 
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Th- l and Th-2 response versus CD8+ CTL response should be looked at more closely to 
determine the roles of these two cytokines in memory cell production. 
The role of CD4+ cytotoxic T cells should also be studied to see if they have a 
potential role in prolonging survival in tumor-bearing rats or provide protection from 
development of tumor. Vaccination has had an important role in reducing the mortality 
and morbidity that is caused by infectious diseases. The ultimate goal of a vaccine is to 
develop long-lived immunological protection, whereby the first encounter with a 
pathogen is 'remembered' ,  which leads to enhanced memory responses that either 
completely prevent reinfection or greatly reduce the severity of disease. 
Many promising opportunities wait to be studied. and they give us reason to 
expect that powerful immunologic therapies will one day become a reality. 
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